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A B S T R A C T
Human milk oligosaccharides (HMOs) are the first prebiotics humans meet in life. HMOs provide many benefits
to infants including impact on gut bacteria, promotion of postnatal brain development, and modulation of the
immune system.
A complex bidirectional communication pathway called the microbiota-gut-brain axis links gut homeostasis
and microbial composition with the central nervous system (CNS). Several mechanisms regulated by the gut
microbiota are known to affect this axis. Dynamics in microbiota composition changes the metabolite profile in
the gut, including neuroactive biomolecules that influence brain function and health. The gut microbiota also
has the potential to affect and interact with the neurologic, immunologic and endocrine pathways of the mi-
crobiota-gut-brain axis.
In this review, we discuss the potential role of HMOs in microbiota-gut-brain axis and CNS disorders, by
describing the role of the gut microbiota in relation to brain health and the importance of dietary interventions
in manipulating the microbiota-gut-brain axis.
1. Introduction
1.1. Microbiota-gut-brain-axis
The gut-brain axis refers to the important bidirectional link between
the gastrointestinal tract and the central nervous system (CNS). It in-
volves direct and indirect pathways between cognitive and emotional
centers in the brain with peripheral intestinal functions (for a thorough
review see: (Cryan et al., 2019)). Accumulating evidence show the
importance of the gut microbiota on the gut-brain axis, demonstrated in
animals as well as humans (Bercik et al., 2011; Savignac et al., 2013;
Schmidt et al., 2015). Therefore, the term “microbiota-gut-brain axis” is
now widely used, as the role of the gut microbiota is not limited to the
intestines. A disruption or alteration of the gut microbiota has been
related to several health burdens and diseases inside and outside the gut
(Minato et al., 2017; Vogt et al., 2017). The link between microbiota
disruption and several conditions makes the gut microbiota a promising
therapeutic target in treating intra- as well as extra-intestinal diseases,
including CNS disorders and it is being greatly investigated in several
animal disease models and intervention studies (Burokas et al., 2017;
Grimaldi et al., 2018; Sampson et al., 2016). The gut microbiota can
interact with the gut-brain axis in different ways, including through an
endocrine, immunologic or neurologic way all discussed in the review
by Cryan et al., from 2019: (Cryan et al., 2019). The gut microbiota is
also highly involved in the production, secretion or regulation of neu-
roactive biomolecules that either directly or indirectly can impact brain
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health or function through the gut-brain axis (Barrett, Ross, O'Toole,
Fitzgerald, & Stanton, 2012; Hata et al., 2017; Rudzki et al., 2019). This
underlines the importance of the gut microbiota in brain health.
1.2. The gut microbiota and its functions
Humans contain approximately 150-fold more bacterial genes than
human genes (Qin et al., 2010). A majority of the microorganisms co-
lonize the gut with the colon holding the highest concentration of
bacteria. The gut microbiota is a diverse and specialized ecosystem
influenced by several factors. Evidence continues to mount, suggesting
that the colonization of the infant gut begins prenatally, in utero
(Dogra, Sakwinska, Soh, Ngom-Bru, Brück, Berger, & Holbrook, 2015;
Hu et al., 2013). Subsequently, the mode of birth delivery (Madan et al.,
2016), milk-feeding (Azad et al., 2013; Bezirtzoglou, Tsiotsias, &
Welling, 2011) and weaning (Odamaki et al., 2016) impacts the bac-
terial colonization the first year of life together with genetics
(Yatsunenko et al., 2012), environmental factors (Stewart et al., 2018),
and medication incl. antibiotic usage (Bennet, Eriksson, & Nord, 2002).
After weaning, the gut microbiota profile begins to be more similar to
adults (Avershina et al., 2016). In adults, the gut microbiota contains a
core community of permanent colonizers with some quantitative fluc-
tuation induced by several introduced changes such as diet and medi-
cation (Arumugam et al., 2011; Rajilić-Stojanović, Heilig, Tims,
Zoetendal, & de Vos, 2013). Some genera are more impacted by
changes through age. As an example, bifidobacteria are the most
abundant genus present in the infant gut (Stewart et al., 2018). During
adulthood the abundance decreases considerably, and remains rela-
tively stable, but further decreases in old age (Kato et al., 2017;
Odamaki et al., 2016). Lower abundance of bifidoacteria has been
found in a variety of diseases, suggesting a role of bifidobacteria in
health (see the following review: (Arboleya, Watkins, Stanton, & Ross,
2016)).
The gut microbiota is constantly modulated by internal and external
factors. Unfavorable alterations in the composition of the gut micro-
biota by factors such as diet, medication or stress can lead to a dis-
ruption in the symbiotic relationship between the host and associated
gut microbiota leading to both external and internal diseases. This kind
of unfavorable alteration in the gut microbiota is defined as dysbiosis.
Contrary, when the gut microbiota can keep living in a mutualistic
relationship with the host without compromising health status, it is
defined as a healthy gut microbiota (Wilkins, Monga, & Miller, 2019).
Several reviews have aimed to describe the exact composition of a
dysbiotic and healthy gut microbiota. However, a lot of variations and
changes can occur in the same individual influenced by e.g. age, diet
and medical use (for reviews on this topic see: (Gagliardi et al., 2018;
Rinninella et al., 2019)). Modulating the gut microbiota has been in-
dicated to be a possible way to not only affect intestinal health but also
affect the brain.
The effect of the gut microbiota on general health has been widely
investigated the last decades, especially by the use of model systems,
including ex vivo, in vitro, germ-free (GF) mice, and knock out models.
Although translational differences exists between these simplified
models and the complexity of a human, these models are highly re-
levant to investigate specific structures and mode of actions (see the
following review for discussion of translation from animal models to
humans in relation to gut microbiota: (Turner, 2018)). By the use of
model systems the gut microbiota has shown to be important in vitamin
synthesis (Gustafsson, 1959), metabolite production (Barrett et al.,
2012; Hata et al., 2017), development of the immune system (Clarke
et al., 2010; Maslowski et al., 2009; Wen et al., 2008), intestinal barrier
homeostasis (Cani, Possemiers, et al., 2009), digestion of complex
macromolecules and gut motility (Husebye, Hellström, Sundler, Chen,
& Midtvedt, 2001). The gut microbiota has also demonstrated to be
relevant in brain health, a relationship that has been thoroughly in-
vestigated by the use of GF animals. Wikoff et al., compared plasma
samples from GF mice with conventional mice and observed differences
in the presence of certain biomolecules (Wikoff et al., 2009). These
biomolecules included the neurotransmitter serotonin, which had a 2.8-
fold higher concentration in the plasma of conventional mice compared
with GF mice (Wikoff et al., 2009). The precursor tryptophan, however,
was higher in the GF animals. Several other studies have also indicated
a strong influence of the gut microbiota and the serotonergic system
(Clarke et al., 2013; Hata et al., 2017; Lukić, Getselter, Koren, & Elliott,
2019), and finally, studies in rats have shown a relationship between
the gut microbiota and brain health and function (Luo et al., 2014;
Savignac et al., 2013). Correlation-studies and interventions studies in
humans substantiates what is seen in the model systems in relation to
the link between gut microbiota and brain health, indicating a trans-
lational possibility.
1.3. Human milk oligosaccharides
Human breast milk, the first and primary nutrition source for the
infant is rich in nutrients, vitamins and bioactive compounds that
support development and growth of the infant. Human breast milk in-
fluences development of the gut microbiota, the immune system and
affects metabolic pathways (for review see: (Hennet & Borsig, 2016)).
Human breast milk contains several important biomolecules such as
lactoferrin, immune components and human milk oligosaccharides
(HMOs). Lactoferrin has important potential in modulating the gut
microbiota, as seen when correlating the amount of fecal bifidobacteria
and lactobacilli and the concentration of fecal lactoferrin
(Mastromarino et al., 2014). Milk also holds a great amount of immune
components like antibodies, cytokines and defensins, to help form the
immune system of the infant. Another important microbiota modulator
and the third most abundant solid bioactive compound in human breast
milk, is HMOs (Tonon, Miranda, Abrão, de Morais, & Morais, 2019).
The remaining part of this review will focus on HMOs and their possible
effect on the microbiota-gut-brain axis.
Around 200 distinct structures of HMOs have been identified, all
having a lactose group on their reducing end (Tonon et al., 2019) (for
review see: (Hennet & Borsig, 2016)). HMOs consist of various combi-
nations of five monosaccharides: galactose (Gal), glucose (Glc), N-
acetylglucosamine (GlcNAc), fucose (Fuc) and sialic acid (Sia) that are
linked via several glycosidic bonds see review by Bode (Bode, 2012).
HMOs can be divided into three groups depending on their chemical
composition: the first group is the neutral core HMOs that contains only
Glc, Gal and GlcNAc. The second group is the neutral fucosylated HMOs
made up of lactose or a neutral core backbone decorated with one or
more Fuc units. The third group is the sialylated HMOs made up of
lactose or a neutral core backbone decorated with one or more Sia units
(Tonon et al., 2019). One example of each HMO-structure is shown in
Fig. 1.
HMOs are resistant to enzyme degradation and acidic conditions
during the passage through the gastrointestinal tract and reach the
colon in an intact form, where only specific gut bacteria are able to
utilize them. The utilization by gut bacteria are highly dependent on
structure, and hence HMOs are used differently depending on species
and strain. Most strains of B. longum subsp. infantis and B. bifidum are
able to utilize several different structures of HMOs (Asakuma et al.,
2011; Yu, Chen, & Newburg, 2013), whereas B. breve strains only grow
on structures belonging to the neutral core group such as Lacto-N-tet-
raose (LoCascio et al., 2007). HMOs can however also indirectly affect
the gut microbiota milieu in different way. HMOs have shown to inhibit
binding and colonization of certain pathogens in the intestine in vitro
(Weichert et al., 2013), interact with the epithelial wall and affect cells
of the immune system (Zhang et al., 2019). These effects help to in-
directly avoid dysbiosis in the intestines (see the thorough review by
Bode: (Bode, 2012)).
A unique characteristic of HMOs is their high concentration and
great structurally diversity in human milk. The concentration of HMOs
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fluctuates during lactation with an estimate of 5–15 g/L present in
human milk with colostrum having the highest concentration (Coppa
et al., 1999; Tonon et al., 2019). The concentration and composition of
the individual HMO-structures are affected both by genetic and non-
genetic factors. Even though carbohydrate synthesis is not genetically
encoded unlike nucleotides and proteins, HMO variability is strongly
dependent on the activity of Secretor and Lewis genes in the mother
(Kunz et al., 2017). No other animal produce the milk oligosaccharides
to the same extent as humans and the concentration in most animal
milk is very low with the range of 0.5–7 g/L with cows having the
lowest and pigs the highest concentration (Tao et al., 2008; Difilippo
et al., 2016). Although the individual structures of milk oligosacchar-
ides are identical in human and animal milk, the sialylated oligo-
saccharides are highest in abundance in animal milk whereas the fu-
cosylated oligosaccharides are highest in abundance in human milk
(Coppa et al., 1999; Difilippo et al., 2016; Tao et al., 2008). It has been
speculated to use bovine milk as a source of milk oligosaccharides for
infant formula, however, as mentioned the concentration of milk oli-
gosaccharides is very low in bovine milk with the majority of sialylated
structures (Martín, Martín-Sosa, García-Pardo, & Hueso, 2001; Tao
et al., 2008). Different groups have examined the effect of bovine milk
oligosaccharides (BMOs). It was found in a study by Lane et al. that
BMOs are able to affect the expression of cytokines and surface re-
ceptors on HT29 cells with a concentration of 4 g/L, which is higher
than the physiological BMOs (Lane, O'Callaghan, Carrington, & Hickey,
2013). This shows that bovine milk holds oligosaccharides which have
immunomodulatory functionality as HMOs. However, the concentra-
tion of oligosaccharides in bovine milk is not sufficient to induce these
effects. Bovine milk still represent a potential source of milk oligo-
saccharides, and it has been speculated that whey permeate might be a
source of the oligosaccharides, however it needs to be further in-
vestigated and optimized (Barile, Tao, Lebrilla, Coisson, Arlorio, &
German, 2009). HMOs have until recently been reserved for breastfed
infants. However, it is now possible to produce some of the most
abundant HMO-structures. Some of the structures industrially produced
includes Lacto-N-neotetraose ((LNnT), 2′-Fucosyllactose (2′FL), 3′-Sia-
lyllactose (3′SL) and 6′-Sialyllactose (6′SL). Toxicology studies of these
show no adverse, genotoxic or mutagenic effects, even at extremely
high supraphysiological doses (Coulet, Phothirath, Allais, & Schilter,
2014; Coulet, Phothirath, Constable, Marsden, & Schilter, 2013;
Monaco, Kim, Gurung, & Donovan, 2020; Parschat, Oehme, Leuschner,
Jennewein, & Parkot, 2020; Phipps, Baldwin, Lynch, Flaxmer, et al.,
2018; Phipps, Baldwin, Lynch, Stannard, et al., 2018; Phipps et al.,
2019a, 2019b; Pitt et al., 2019). In clinical trials, 2′FL, LNnT and 3′SL
have shown to be safe and well-tolerated in infants and adults (Elison
et al., 2016; Kim, 2018; Puccio et al., 2017). Several products including
infant formulas and digestive health products can now be found on the
market with 2′FL and LNnT.
The most tested HMOs in humans are 2′FL and LNnT.
Administration of 2′FL to infants have shown to lower the inflammatory
cytokine profile in infants receiving infant formula compared to control
group, mimicking the situation in breastfed infants (Goehring et al.,
2016), and induce better cognitive development in infants in the first
months (Berger, Plows, et al., 2020). A combination of 2′FL and LNnT
have also shown to lower morbidity and decrease medical use in infants
(Puccio et al., 2017). Supplementation of 2′FL and LNnT have also
shown to modulate the gut microbiota specifically increasing the re-
lative abundance of bifidobacteria in infants (Berger, Porta, et al.,
2020) and adults (Elison et al., 2016) compared to controls. These
clinical studies indicate that HMOs have a potential in general health.
This review will discuss the potential role of the HMOs and CNS health
by communicating through the microbiota-gut-brain axis.
2. How the microbiota can impact the brain
The gut microbiota can affect brain health in different ways e.g.
through the neurologic, immunologic or endocrine pathways. Another
way is by the regulation and production of numerous neuroactive
biomolecules. These biomolecules are either produced directly during
bacterial degradation of fibers or their biosynthesis is regulated by the
gut microbiota. These neuroactive biomolecules function by stimulating
the CNS and its processes. Among the neurotransmitters known to be
influenced by the gut microbiota are ferulic acid (FA) (Szwajgier &
Anna, 2010; Tomaro-Duchesneau et al., 2012), short chain fatty acids
(SCFAs) (Baxter et al., 2019), gamma-aminobutyric acid (GABA)
(Barrett et al., 2012), tryptophan (Gao et al., 2019; Rudzki et al., 2019)
and serotonin (Hata et al., 2017; Yano et al., 2015).
FA, is a phenolic acid found in a vairety of plant structures including
grains, seeds and leaves. FA exists freely but a fraction is linked to the
plant cell by covalent bonds. Ferulic acid esterase (FAE) produced by
bacteria can cleave the ester-bound FA making it available in the gut.
FA has potential anti-inflammatory properties and inhibits generation
of reactive oxygen species (ROS) (Chen et al., 2017; Maurya &
Devasagayam, 2010). Increased ROS has been shown to play a role in
Fig. 1. Examples of the three different HMO-structures. 2′FL is an example of a neutral fucosylated HMO and the most abundant HMO in human milk, LNnT is among
the neutral core HMO-structures and 3′SL is a sialylated HMO. Abbreviations used in this figure: HMO (human milk oligosaccharide); LNnT (Lacto-N-neotetraose);
2′FL (2′-Fucosyllactose); 3′SL (3′-Sialyllactose).
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the development of neurodegenerative diseases see the following re-
view: (Nissanka & Moraes, 2018). Moreover it has been shown by Yabe
et al., that FA induces proliferation of adult neural stem cells and sti-
mulates the expression of brain derived neurotrophic factor (BDNF) in
the hippocampus of corticosterone-treated mice (Yabe et al., 2010).
BDNF induces the differentiation and survival of cholinergic neurons in
the basal forebrain (Ward & Hagg, 2000), as well as the secretion of
acetylcholine. When BDNF is inhibited it results in cognition decline
(Şahin et al., 2015). This indicates that promoting the right bacteria
might increase FA-production and thereby increase brain health.
Similarly, SCFAs such as butyrate, acetate and propionate play im-
portant roles both intra- and extra-intestinally. SCFAs are produced by a
range of different bacterial species. When bifidobacteria produce lac-
tate and acetate, butyrate-producing bacteria can convert these meta-
bolites to butyrate, a process known as cross-feeding (Schwab et al.,
2017). SCFAs may act as endocrine signaling molecules that enter
systemic circulation from the gut, cross the BBB through mono-
carboxylate transporters and reach the brain where these compounds
can directly influence brain function, and SCFAs have also shown to
improve BBB permeability in mice (Braniste, et al., 2014). SCFAs have
also been shown to modulate synthesis and expression of nicotinic and
GABA receptors (Nankova, Agarwal, MacFabe, & La Gamma, 2014),
and can regulate the expression of tyrosine hydroxylase, an enzyme that
plays an important role in the production of catecholamines, and is
responsible for dopamine synthesis, degradation and transport
(DeCastro et al., 2005). Furthermore, butyrate has been shown to sti-
mulate the biosynthesis of BDNF in the frontal cortex in mice
(Schroeder, Lin, Crusio, & Akbarian, 2007). Finally, GABA inhibits sy-
naptic transmission in the brain, as it is the major inhibitory neuro-
transmitter of the CNS, and especially GABA produced from the gut
microbiota has been suggested to have an impact on the gut-brain axis
(Barrett et al., 2012; Strandwitz et al., 2019).
Tryptophan is an amino acid and a precursor to important neu-
roactive molecules. Tryptophan can either enter the kynurenine or the
serotonin pathway. The serotonergic system has shown to be involved
in several CNS disorders such as depression (Kelly & Borre, 2016;
Owens & Nemeroff, 1994) and ASD (Boccuto et al., 2013). The ser-
otonergic system is a highly relevant player in the microbiota-gut-brain
axis, as a fraction of serotonin is synthesized from tryptophan by the
enterochromaffin cells in the gut and some bacteria strains, like Lac-
tobacillus, have also shown to directly synthesize serotonin from tryp-
tophan in vitro (Özoǧul, Kuley, Özoǧul, & Özoǧul, 2012). The kynur-
enine pathway on the other hand, leads to the production of kynurenine
which can be further metabolized to 3-hydroxykynurenine and quino-
linic acid, which have demonstrated to be neurotoxic. The gut micro-
biota has shown to impact the balance between the tryptophan de-
gradation pathways and serotonin synthesis (Desbonnet, Garrett,
Clarke, Bienenstock, & Dinan, 2008; Ge et al., 2017). As an example, an
altered dysbiotic microbiota composition is often accompanied by an
inflammatory state in the gut which can induce production of cytokines
such as interferon-gamma (IFN-γ). Indoleamine 2,3-dioxygenase (IDO)
is the rate limiting factor converting tryptophan to kynurenine in the
kynurenine pathway, and is regulated by inflammation and IFN-γ
(Jürgens, Hainz, Fuchs, Felzmann, & Heitger, 2009). Increased IFN-γ in
a proinflammatory dysbiotic environment will alter the ratio of ky-
nurenine:tryptophan. Kelly et al., showed that a fecal transfer from
depressed patients to microbiota-depleted rats induced behavioral and
physiological features characteristic of depression in the recipient ani-
mals including increased kynurenine:tryptophan metabolism (Kelly &
Borre, 2016). This means a shift in the processing of tryptophan, lim-
iting the amount of tryptophan entering the serotonergic pathway. In
this way a dysbiotic microbiota composition can affect the serotonergic
system contributing to different CNS disorders. This was illustrated in a
study by Ge et al., where administration of antibiotics to mice de-
creased the diversity of the gut microbiota as well as serotonin levels
(Ge et al., 2017). In contrast, a study by Desbonnet et al., showed that
administration of a probiotic, Bifidobacterium infantis, increased plasma
tryptophan and decreased pro-inflammatory cytokines in rats
(Desbonnet et al., 2008). This illustrates a potential for the gut micro-
biota to not only affect the serotonergic system, but also regulating the
immune system, another microbiota-gut-brain axis-pathway. Valles-
Colomer et al., demonstrated that the microbiota phenotype is linked to
mental health in humans (Valles-Colomer et al., 2019) and in a double
blind, randomized, placebo controlled trial it was found that adminis-
tration of probiotics (Lactobacillus Plantarum 299v), lowered the amount
of kynurenines and improved cognitive functions in patients with major
depressive disorder significantly (Rudzki et al., 2019), underlining the
importance of the gut microbiota in mental health.
The link between gut microbiota and brain health has been de-
monstrated in different studies. The gut microbiota is important for the
development of an intact blood-brain barrier as shown in a study by
Braniste et al., using GF mice. The GF mice had a more permeable BBB
and lower expression of brain tight junction proteins compared to
conventional mice. Interestingly, by inoculating GF mice with pa-
thogen-free gut microbiota, the permeability of the BBB decreased
(Braniste et al., 2014). Other studies in GF mice have demonstrated the
influence of the gut microbiota on the expression of BDNF in the CNS
(Arentsen, Raith, Qian, Forssberg, & Diaz Heijtz, 2015; Gareau et al.,
2011). BDNF has shown to play an important role in the development
and differentiation of neurons in murine models (Rauskolb et al., 2010;
Strand et al., 2007), but is also believed to be important for learning
and development of memory in humans, as showed by Egan et al., and
Hariri et al., (Egan et al., 2003; Hariri et al., 2003). This is consistent
with a study showing that decreased levels of hippocampal BNDF in
mice is associated with anxiety- and depression-like behavior (Burokas
et al., 2017).
Dysbiotic alterations in the composition of the gut microbiota, can
therefore have a major impact on the gut-brain-axis associated condi-
tions such as irritable bowel syndrome (IBS) (Kassinen et al., 2007),
Alzheimer's disease (AD) (Vogt et al., 2017), Parkinson's disease (PD)
(Minato et al., 2017; Sampson et al., 2016), autism spectrum disorder
(ASD) (Liu et al., 2019) (Tomova et al., 2015), and major depression
disorder (Jiang et al., 2015). These dysbiotic alterations include de-
creases in bifidobacteria, as well as a higher number of gram-negative
bacteria and a decreased microbial diversity. In addition, gastro-
intestinal disturbances are among the early symptoms of neurodegen-
erative diseases, indicating that dysbiosis may participate in triggering
diseases in the CNS (Forsyth et al., 2011). Thus, it is becoming clear
that the gut microbiota is a critical component of the gut-brain axis, not
only by regulating brain function, but also by regulating the physical
development of the brain, as investigated by Heijtz et al., by the use of
GF mice (Heijtz et al., 2011). Therefore, the gut microbiota might have
great potential in the therapeutic field of CNS disorders, and modula-
tion of the gut microbiota have been investigated as possible treatment
options (Allen et al., 2016; Hadizadeh, Hamidi, & Salami, 2019; Pinto-
Sanchez et al., 2017; Rudzki et al., 2019). In this section the focus has
primarily been on the regulation of neuroactive biomolecules produced
or regulated by gut microbiota, however, the microbiota-gut-brain axis
includes several other pathways such as immunologic, neurologic and
endocrine pathways. The neuroactive biomolecules introduced above
also function by different mechanisms. Some work directly in the brain,
whereas others regulates homeostasis and thereby indirectly affect
brain health and function.
3. Modulation of the microbiota-gut-brain axis through the diet
As mentioned above, the gut microbiota composition and activity
can be altered by diet and environmental factors (Tarr et al., 2015). In
fact, diet is one of the most potent modulators of the gut microbiota. Wu
et al., found that a Western diet dominated by proteins and animal fat
induced a different gut microbiota profile compared with a diet high in
fiber (Wu et al., 2011). This observation was also seen in a study by De
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Filippo et al., where rural African children with a diet high in fiber
content had a significantly different gut microbiota profile with a
higher abundance of SCFA-producing bacteria compared with European
children (De Filippo et al., 2010). In addition, a different SCFA-meta-
bolite-profile have been observed in humans with inflammatory bowel
disease compared to healthy controls (Zhuang et al., 2019). This in-
cludes decreased levels of total SCFA as well as the individual structures
of acetate and valerate. Thus, modulating the gut microbiota through
diet to improve the SCFA-profile could be a way to impact the micro-
biota-gut-brain axis and as a consequence improve health, as SCFAs also
have other beneficial effects e.g. on the immune system (Haghikia et al.,
2015). Sia is another compound obtained through diet essential for
development and cognition (see review by Wang: (Wang, 2009)). Sia is
a part of the gangliosides and the polysialic acid chains in the brain.
Gangliosides are Sia-containing glycosphingolipids. These structures
possess several important functions in relation to brain health and de-
velopment. They have been indicated to be implicated in embryonic
neural development and neuronal plasticity as well as potentiating
long-term potentiation (LTP). The amount of ganglioside has been
shown to be involved in different diseases and conditions (see review by
Schengrund: (Schengrund, 2015)). Dietary supplemented with Sia has
demonstrated increased learning and memory in piglets (Wang et al.,
2007). This indicates a need for Sia in the brain, and dietary inter-
ventions are one way to obtain this. Biomolecules can be synthesized
from undigested food products that reach the colon, which emphasize
the importance of the diet in production of these essential molecules in
managing brain health. Indigestible dietary fibers can impact the gut
microbiota composition, in particular increasing saccharolytic bacteria,
leading to the production of SCFAs, like butyrate. A majority of the
produced butyrate is used by the colonocytes as an energy source
(Donohoe et al., 2011). The rest enters the bloodstream and is either
absorbed by the liver or enters systemic circulation. Wolever and
Chiasson showed in a randomized, double-blind, placebo-controlled
trial using subjects with impaired Glc-tolerance that treatment with
acarbose (an anti-diabetic drug) caused an increase in acetate and bu-
tyrate concentrations in serum. This was argued to be caused by the
effect of acarbose increasing the entry of indigestible dietary fibers into
the colon, and hence stimulating saccharolytic bacteria (Wolever &
Chiasson, 2000). The increase of circulating butyrate could have a di-
rect function on the CNS. This has been shown in a pig model, where
oral butyrate impacted brain metabolism and hippocampal neurogen-
esis (Val-Laillet et al., 2018). In addition, other studies have demon-
strated that a diet high in fiber can influence the brain by providing it
with essential nutrients for development, decreasing neuroinflamma-
tion, and supply of energy (Khan et al., 2015). In relation to this, an-
other study observed a decrease in butyrate producing bacteria in pa-
tients with depression, demonstrating a link between gut, microbiota
and brain health (Valles-Colomer et al., 2019).
New nutritional strategies to improve microbiota-gut-brain health
are currently under investigation and are generating increasing interest.
These strategies include the use of probiotics. A clinical study by
Messaoudi et al., showed that the administration of probiotics
(Lactobacillus helveticus and Bifidobacterium longum) alleviated psycho-
logical distress in rats and healthy volunteers (Messaoudi et al., 2011).
In another trial, probiotic administration of Bifidobacterium longum re-
duced depression, but not anxiety scores in IBS patients. These im-
provements were associated with changes in brain activation patterns
indicating that administration of Bifidobacterium longum reduced limbic
reactivity (Pinto-Sanchez et al., 2017). Results as these have suggested
a relevance for probiotics in brain health and function.
Also prebiotics have been thought to have a beneficial effect.
Prebiotics is defined as: “A substrate that is selectively utilized by host
microorganisms conferring a health benefit” (Gibson et al., 2017). Some
well-known prebiotics are oligosaccharides such as fructooligo-
saccharides (FOS) and galactooligosaccharides (GOS) or saccharide
polymers such as inulin. Prebiotics have been shown to stimulate the
growth of bifidobacteria and lactobacilli in the colon resulting in lower
pH, due to the production of organic acids (Yu et al., 2013). In one
study, FOS and GOS supplementation in rats influenced the composi-
tion of the gut microbiota and increased hippocampal BDNF expression,
which was suggested to function through the production of gut hor-
mones (Savignac et al., 2013). In a human trial, consumption of inulin
caused an increase in gut microbiota fermentation, decreased appetite,
improved postprandial Glc-responses and increased the concentrations
of the two gut satiety hormones glucagon-like peptide 1 and peptide YY
(Cani, Lecourt, et al., 2009). Both satiety hormones have been shown to
be influenced by changes in the gut bacteria and particularly SCFAs by
the use of knock-out animal models (Samuel et al., 2008; Tolhurst et al.,
2012). As previously discussed, another available prebiotic is HMOs.
HMOs have been shown to be essential for shaping the enteric micro-
biota of the infants (Berger et al., 2020; Marcobal et al., 2010). Also,
fecal samples from breast-fed infants carry a more uniform microbiota
population with a higher number of bifidobacteria compared with
formula-fed infants that were not exposed to HMOs (Bezirtzoglou et al.,
2011). HMOs have also shown to affect brain health and function,
which is further discussed in Section 5.
4. HMOs and their impact on the gut microbiota and potential to
affect the microbiota-gut-brain axis
HMOs have various biological functions, such as preventing the
attachment of pathogens to epithelial cells (Ruiz-Palacios, Cervantes,
Ramos, Chavez-Munguia, & Newburg, 2003) and modulating immune
cell responses (Zhang et al., 2019) in vitro, as well as specifically
modulating gut microbiota in infants as well as healthy and diseased
adults (Berger et al., 2020; Elison et al., 2016; Iribarren et al., 2020)
(for a review see: (Bode, 2012)). Yu et al., demonstrated the specific
stimulation of gut bacteria by fucosylated HMOs (2′FL, 3FL and DFL) in
an in vitro anaerobic culture system using infant fecal microbiota. By
adding HMOs, the growth of bifidobacteria was stimulated with an
increase in lactate production and a decrease in pH. In parallel, sup-
plementation of FOS was investigated and the results showed that the
production of organic acids was higher with HMO supplementation (Yu
et al., 2013). In a clinical trial in infants, it was found that 2′FL and
LNnT were safe, well tolerated and could shift the gut microbiota,
particularly by increasing bifidobacteria, getting a phenotype closer to
that observed in breastfed infants (Berger et al., 2020; Puccio et al.,
2017). Interestingly, clinical trials using 2′FL and LNnT supplementa-
tion in healthy adults and IBS patients also showed modulation of the
gut microbiota with increase in the abundance of bifidobacteria (Elison
et al., 2016; Iribarren et al., 2020)
As mentioned, HMOs impact the composition of the gut microbiota,
especially by inducing the growth of bifidobacteria (Elison et al., 2016).
Bifidobacterium spp. are important members of the gut bacterial com-
munity, particularly due to their production of SCFAs, such as acetate
and lactate. These can later serve as substrates for other bacteria that
produce butyrate (Rivière, Gagnon, Weckx, Roy, & De Vuyst, 2015;
Schwab et al., 2017). In CNS disorders like AD and ASD an altered
microbiota composition has been associated with a particularly de-
creased level of Bifidobacterium (Vogt et al., 2017; Xu, Xu, Li, & Li,
2019). Manipulating the gut microbiota is recently being speculated as
an alternative treatment for ASD (Grimaldi et al., 2018). Similar ob-
servations have been seen in patients with depression, holding a de-
creased amount of butyrate producing bacteria (Valles-Colomer et al.,
2019). Furthermore, alterations in the gut microbiota profile of PD
patients have also been observed and linked to reduced levels of fecal
SCFAs. In a study investigating the gut microbiota composition of
healthy individuals and PD patients, an increase in proinflammatory
Proteobacteria species and a decrease in butyrate-producing bacteria of
the genera Roseburia and Faecalibacterium was observed in PD patients
(Keshavarzian et al., 2015). Hence, we speculate that increasing the
amount of butyrate-producing bacteria and thereby the amount of
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butyrate could have advantageous effects in PD patients. Since HMOs
have been shown to stimulate the growth of bifidobacteria and by cross-
feeding increase the production of butyrate, we speculate that this
could contribute to attenuating the symptoms of PD patients. By in-
ducing the production of SCFAs, HMOs may be a useful tool in long-
term management of different CNS disorders.
GABA is important in the microbiota-gut-brain axis, and certain
Bifidobacterium and Lactobacillus species including L. brevis and B.
adolescentis contain genes responsible for the biosynthesis and transport
of GABA (Siragusa et al., 2007; Barrett et al., 2012). These species
convert monosodium glutamate into GABA in the gut by the enzyme
glutamate decarboxylase (Komatsuzaki, Nakamura, Kimura, & Shima,
2008). GABA regulates the production of acetylcholine, dopamine, and
serotonin, and hence could potentially be a target for CNS diseases like
AD. Dysfunction of the GABAergic system have shown to contribute to
the development of stress-related conditions, memory and cognitive
impairments, as demonstrated in a murine model by Bravo et al., (Bravo
et al., 2011). Interestingly, decreased levels of GABA in the frontal,
temporal and parietal cortex have been observed in AD patients (Lowe
et al., 1988). Therefore, a dysbiotic microbiota causing a reduction in
GABA-producing bacteria species in the gut could result in reduced
levels of GABA, and correlate with a decrease of GABA in the CNS. We
hypothesize that HMOs could increase the production of GABA through
stimulation of GABA-producing bacteria like the bifidobacteria in the
gut and increase levels of GABA available to the CNS.
Several neurodegenerative diseases, including AD, PD and several
others, are known to be related to increased ROS in the CNS, see the
following review: (Nissanka & Moraes, 2018). FA is a potent anti-
oxidant that neutralizes ROS (Ogiwara et al., 2002), and recovers mi-
tochondrial membrane potential. It has also been shown in a sea urchin
embryo model system that FA blocks genes related to apoptosis (Picone,
Nuzzo, & Di Carlo, 2013). Some gut bacteria, including some Bifido-
bacterium spp., are capable of producing FAE (Kelly, O’Callaghan,
Kinsella, & van Sinderen, 2018; Szwajgier & Anna, 2010), an enzyme
involved in synthesizing FA (Tomaro-Duchesneau et al., 2012). By sti-
mulating the beneficial FAE-producing bacteria, HMOs could indirectly
participate in increasing the amount of FA and thereby neutralize the
ROS accumulation present in different neurodegenerative diseases.
Managing the gut microbiota by HMOs, might also be one way to
control the serotonergic system, known to be involved in numerous
diseases, including CNS disorders. As stated earlier, tryptophan and its
metabolite serotonin are strongly influenced by the gut microbiota. A
dysbiotic environment in the gut may result in inflammation with an
effect on the serotonergic system, IFN-γ and the ratio of kynurenine:-
tryptophan. It has been shown in rats that bifidobacteria decrease IFN-γ
and other inflammatory components, as well as alter the
kynurenine:tryptophan ratio (Desbonnet et al., 2008). In another study
in rats it was shown that depressed animals had a higher kynur-
enine:tryptophan ratio, and a decreased amount of different bacteria,
including bifidobacteria (Kelly & Borre, 2016). It has also been shown
that administering probiotics (Lactobacillus helveticus and Bifido-
bacterium longum) to patients with major depressive disorders have a
potential in lowering the kynurenine:tryptophan ratio (Kazemi,
Noorbala, Azam, Eskandari, & Djafarian, 2019). HMOs are known for
their prebiotic effect and their ability to specifically stimulate bifido-
bacteria in the gut of children as well as adults (Elison et al., 2016;
Lawson et al., 2019). A healthy gut bacteria composition might be
useful in a variety of CNS disorders related to tryptophan and serotonin
metabolism, and HMOs could play an important role in helping with
this. HMOs and their effect on the microbiota-gut-brain axis is therefore
highly relevant, as it exerts great potential in managing some CNS
disorders. Production and regulation of neuroactive biomolecules is one
way HMOs might affect the microbiota gut-brain axis, especially due to
their increase in bifidobacteria. However, HMOs could also affect the
microbiota gut-brain axis through neurologic, immunologic or endo-
crine pathways. Neuroactive molecules can also exert effect on the
brain through different mechanisms. For an overview of this hypothesis
see Fig. 2.
Even though a lot of experiments in vitro and in vivo and a lot of
correlations studies suggest a great role for HMOs in modulation of the
gut microbiota, clinical trials investigating this aspect is still at its in-
fancy. A lot of studies are ongoing, and hopefully more studies will
address this aspect in future. However, some clinical studies have al-
ready evaluated this effect and are listed in Table 1.
In one clinical study, Elison et al., demonstrated a modification of
the adult gut microbiota after administration of 2′FL and LNnT. The
study showed substantial increase in the abundance of Actinobacteria
and Bifidobacterium and a reduction in the abundance of Firmicutes and
Proteobacteria (Elison et al., 2016). A similar finding was seen in the
study by Berger et al., that demonstrated an increase in bifidobacteria
in infants (Berger et al., 2020). These studies were both conducted in
healthy population. Another study has shown that 2′FL and LNnT could
impact the gut microbiota in IBS patients increasing the abundance
bifidobacteria (Iribarren et al., 2020). Even though the clinical trials
regarding administration and microbial shift are limited, they all point
to the same conclusion, backing up preclinical data and correlation-
studies: HMOs are able to impact the gut microbiota in infants and
adults, favoring a healthy gut microbiota and inhibiting harmful pa-
thogens that might disrupt the healthy symbiotic relationship in the
gut. More clinical studies are needed to address more HMO-structures,
investigate the kinetics and different populations groups (e.g. sex, age
and health status).
Fig. 2. The hypothetical impact of HMOs on the production and regulation of neuroactive molecules. HMOs are administered (1) and induce the growth of beneficial
bacteria species, like Bifidobacterium spp. (2) which promote the production or activation of important biomolecules, like the SCFAs, GABA and FA (3). These
molecules can either activate the vagus nerve (4), enter the systemic circulation (5), affect the immune system (6) or interact with the microbiota-gut-brain axis
through other unknown mechanisms (7) and in that way impact brain functions (8). Abbreviations used in this figure: HMOs (human milk oligosaccharides); FA
(ferulic acid); GABA (gamma-aminobutyric acid); SCFAs (short-chain fatty acids).
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
6
A lot of the above-mentioned mechanisms build on the impact
HMOs have on the gut microbiota and focus on the production and
regulation of neuroactive molecules. However, as will be illustrated in
the next section, different pathways exist when linking the gut and its
microbiota to the brain. Biomolecules will often have various functions
impacting the brain both directly or indirectly and will be a part of
more than one pathway.
5. HMOs and their effect in brain health and function
Already several decades ago it was found that breastfed infants
showed better cognitive results compared to formula-fed infants. In
1990, Lucas et al., demonstrated that human milk promotes postnatal
brain development in preterm infants. Lucas et al., compared the cog-
nitive development of infants fed formula without HMOs to breastfed
infants, showing improved cognitive capacities in preterm breastfed
infants up to 18 months of age (Lucas et al., 1990). At the age of
7.5–8 years old the children who received their mother’s milk were
doing significantly better in intelligence tests compared to the formula
fed (Lucas, Morley, Cole, Lister, & Leeson-Payne, 1992). Part of this
effect could be due to HMOs. In addition, already in the early nineteens,
several studies have examined the impact of HMOs either directly or
indirectly on brain health and function. In 1994, Krug et al., showed
that 2′FL increased LTP in rats (Krug, Wagner, Staak, & Smalla, 1994),
and in 1996, Matthies et al., found that 2′FL increased population spike
amplitude and field excitatory postsynaptic potential, and had positive
effect on LTP in rat brains (Matthies, Staak, & Krug, 1996). Contrary,
3FL had no effect on LTP, indicating a structural importance of the
HMOs in relation to brain-effect.
In recent years several other studies conducted in animals have
investigated the effect of specific HMOs on the function of CNS. As
previously mentioned, the most commonly used HMO is 2′FL. This
HMO-structure have been tested in different experiments related to
brain health and function. Vázquez et al., showed that dietary supple-
mentation with 2′FL, improved learning and memory skills and im-
pacted brain function in mice and rats (Vázquez et al., 2015). The ad-
ministration of 2′FL was also linked to improvements in LTP, as seen in
some of the earliest studies. In another study, it was shown that 2′FL
affected brain function and cognition through the vagus nerve in male
adult rats (Vazquez et al., 2016). This was investigated by vagotomy of
the animals prior to operant conditioning and LTP measurements. An-
imals receiving 2′FL and sham surgery reached the selected criterion in
the operant conditioned test in less sessions than the 2′FL-vagotomized,
the control-vagotomized and the control-sham groups. The same was
seen in regard to LTP. The 2′FL sham-operated group presented sig-
nificantly larger LTP values than the other three groups (Vazquez et al.,
2016). Interestingly, it was also shown that fucose did not have the
same effect on LTP when administered orally. This suggests the ne-
cessity of 2′FL integrity to exert effects on CNS function (Vazquez et al.,
2016), although the exact mechanism of how the HMOs can affect the
microbiota-gut-brain axis is not yet understood. It was demonstrated in
a metabolic study in mice by Kuntz et al., using labelled 2′FL that it
does not reach the brain in its intact form. The majority of the 2′FL
either applied intravenously or orally ended up in the gut, and was
suggested to be modulated by the microbiota as differences were ob-
served when comparing plasma levels of 2'FL in GF mice to wild type
mice (Kuntz et al., 2019). This could suggest that the impact of 2′FL on
the brain is depending on the gut microbiota. Still there is also the
possibility that the signaling to the brain happens through another
microbiota-gut-brain pathway e.g. the vagus nerve, as was demon-
strated by Vazquez. In another study by Bravo et al., Lactobacillus.
rhamnosus altered GABA-receptor expression in the brain and reduced
stress-induced corticosterone and anxiety- and depression-related be-
havior in mice. These neurochemical and behavioral effects were not
seen in vagotomized mice, also pointing to the vagus nerve as a relevant
communication pathway between the gut bacteria and the brain (BravoTa
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et al., 2011).
2′FL has also demonstrated to have a stress-reversing effects on
intestinal motility and propagating contractile clusters. This was in-
vestigated in two different studies (Bienenstock et al., 2013; Farhin
et al., 2019). In addition, 2′FL has been shown to change the compo-
sition of cecal microbiota and metabolites in mice compared to low-fat
diets and high fat diets, and modulated hyperphagic response to high-
fat diets. In this study, there was a hint that the vagus nerve could be
involved, however, the findings were not significant (Lee et al., 2020).
It was recently reported that 2′FL has beneficial effects in a murine
stroke-model. 2′FL reduced neurotoxicity, apoptosis, and Ca++ influx
in primary neuronal culture. Treatment with 2′FL before or after the
induction of the stroke reduced brain infarction, motor deficits and
inflammation and caused an increase in the expression of BDNF and
glial cell-derived neurotrophic factor (Wu et al., 2020). These findings
indicate that 2′FL might have a relevant role in brain health and
function, but a lot remains to be investigated, including the mode of
action and the involved microbiota-gut-brain pathway.
Other relevant HMO-structures related to brain health are the sia-
lylated HMOs. The most common ones are 3′SL and 6′SL. Sia has shown
to be important in neurodevelopment which has been illustrated in
several studies and collected in a review by Wang (see review: (Wang,
2009)). As mentioned in previous section, dietary Sia can improve
learning and memory in piglets evaluated by the use of 8-arm radial
maze (Wang et al., 2007). It has also been evaluated that infants fed
infant formula have significantly lower levels of Sia in the frontal cortex
compared to breastfed children (Wang, McVeagh, Petocz, & Brand-
Miller, 2003). Knowing the structure and prevalence of HMOs, com-
bined with the knowledge that a substrate in human milk is a great
source for Sia in the brain, suggests that sialylated HMOs might be a
great source of Sia in brain development. The findings of Sia as an
important neurodevelopmental modulator points to the need of a Sia
source in infants. Recent years, more studies have been performed ad-
dressing the sialylated HMOs in the aspect of brain function and brain
health.
Oliveros et al., showed that 6′SL improved memory and LTP in rats.
The rats receiving Sia and especially the ones receiving 6′SL, did sig-
nificantly better in the behavioral assessment and showed an enhanced
LTP compared to controls (Oliveros et al., 2018). Additionally, Tarr
et al., investigated the impact of 3′SL and 6′SL on stressor-induced al-
terations in the gut microbiota of mice and behavior related to stress. A
significant alteration in the colonic microbiota composition of the
control mice wase observed, as well as development of anxiety-like
behavior. This was not observed in mice fed HMOs, indicating impact of
HMOs on behavior related to stress and anxiety (Tarr et al., 2015).
Jacobi et al., investigated impact of 3′SL and 6′SL on brain Sia and gut
microbiota of neonatal pigs. They observed an increase in ganglioside
Sia in the brain of piglets fed the sialylated HMOs and a positive change
in the colonic microbiota composition (Jacobi et al., 2015). Recently,
Wang et al., showed that sialylated oligosaccharides could increase the
amount of several neuroactive biomolecules in piglets (Wang et al.,
2019). Even though 3′SL and 6′SL show promising results in relation to
brain health and function, Fleming et al., found that sialyllactose (SL)
had no effect on recognition memory or diurnal activity in piglets
(Fleming, Chichlowski, Berg, Donovan, & Dilger, 2018). Additionally
Mudd et al., showed no difference in total and free Sia concentrations in
the brain after dietary supplement of SL. However, it was shown that
dietary SL in low or moderate concentrations decreased the amount of
bound Sia in prefrontal cortex, and moderate concentration of SL in-
creased the ratio of free-to-bound Sia in hippocampus compared to
controls (Mudd et al., 2017). It was, however, not indicated which type
of SL was used in these studies and it has been demonstrated that the
structure complexity is important for brain health. Both studies used
380 mg SL/L (moderate concentration in the study by Mudd et al).
These concentrations are lower than the concentration used in other
brain-related studies focusing on SL (Jacobi et al., 2015; Wang et al.,
2019), indicating that a certain amount of SL is necessary to obtain the
beneficial effects. However, in a recent study by Obelitz-Ryom et al., a
similar low concentration of SL showed significant results in preterm
pigs. The preterm pigs did better on preference test and had increased
genes related to Sia metabolism, myelination, and ganglioside bio-
synthesis in hippocampus. The study showed that SL supplementation
did not increaselevels of Sia in hippocampus, and the effect might
therefore be related to another microbiota-gut-brain pathway (Obelitz-
Ryom et al., 2019). The formulation of the Sia fed through the diet
might also be of significant matter, as other Sia-containing compounds
have shown a beneficial effect (Wang et al., 2007). The administration
of 3′SL and 6′SL did however induce beneficial properties in other
studies, and more studies are therefore needed to evaluate if optimi-
zation of the kinetics could induce a response. Sialylated HMOs might
also affect the microbiota-gut-brain axis through another mechanism
than just delivering Sia to the brain, however more studies are needed
to fully evaluate the potential of sialylated HMOs as a modulator of the
microbiota-gut-brain axis, but the studies performed so far provides a
good indication of a positive effect of sialylated HMOs, when given in
the right concentrations.
Collectively, these findings show a relation between modulation of
the gut microbiota and brain function after digestion of certain HMOs
and allow us to suggest that HMOs may impact the brain through the
microbiota-gut-brain axis. Several different ways have been suggested
and some studies have shown the involvement of the vagus nerve
(Vazquez et al., 2016). Studies evaluating the direct effect of HMOs on
brain health and function are performed in animals, and of course
human trials will need to be performed to fully understand the effect
HMOs have on brain health and function. However, the above de-
scribed experiments indicate that HMOs could be relevant in brain
health, even though the specific mode of action is still to be unraveled.
HMO-studies investigating brain health or function are summarized in
table 2 below.
6. Conclusion
Dietary modulation of the gut microbiota is a promising tool in the
management of intra- and extra-intestinally diseases. Inducing a shift in
the gut microbiota towards a healthy composition could be a target to
improve brain health. A microbial shift could induce beneficial prop-
erties via the gut-brain axis in several ways, including the production of
bacterial derived biomolecules, or affecting neurologic, immunologic or
endocrine pathways directly or indirectly. HMOs are resistant to de-
gradation by host enzymes, and therefore reach the colon undigested,
and are available as nutrients for specific gut bacteria. HMOs have long
been known to be important for infant health, and are now also known
to specifically change the gut microbiota, in particular bifidobacteria in
adults. Several animal studies have shown a beneficial impact of HMOs
on brain function through the microbiota-gut-brain axis. Even though
the specific mode of action of HMOs in brain health still remains to be
elucidated, we speculate that HMOs could be a choice for nutritionally
managing symptoms related to the CNS.
7. Ethics statements
The research did not include any human subjects or animal ex-
periments.
CRediT authorship contribution statement
Alia H. Al-Khafaji: Conceptualization, Writing - original draft,
Investigation, Visualization. Stine Dam Jepsen: Conceptualization,
Writing - original draft, Investigation, Visualization. Kristine Rothaus
Christensen: Writing - review & editing. Louise Kristine Vigsnæs:
Conceptualization, Writing - review & editing, Supervision, Project
administration.
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
8
Ta
bl
e2
Lit
era
tu
re
ov
erv
iew
inc
lud
ing
HM
O-
stu
die
sr
ela
ted
to
br
ain
he
alt
h
or
br
ain
fun
cti
on
.A
bb
rev
iat
ion
su
sed
in
th
e
tab
le:
GF
(ge
rm
-fr
ee
);
LT
P
(L
on
g-t
erm
po
ten
tia
tio
n)
;S
ia
(si
ali
c
ac
id)
;S
L
(si
aly
lla
cto
se)
;2
′FL
(2
′-
Fu
co
sy
lla
cto
se)
;3
FL
(3
-Fu
co
sy
lla
cto
se)
;3
′SL
(3
′-S
ial
yll
ac
tos
e);
6′S
L(
6′-
Sia
lyl
lac
tos
e).
Str
uc
tu
re(
s)
Co
nc
en
tra
tio
n+
du
rat
ion
Ty
pe
of
stu
dy
Inv
est
iga
tio
n
N
Ou
tco
me
Re
fer
en
ce
2′F
L
1.5
uL
of
30
mm
ol
so
lut
ion
of
2′F
L
inj
ec
ted
int
oc
or
pu
sc
all
os
um
.
In
viv
o:
W
ist
ar
rat
s,
22
0–
24
0g
,m
ale
s.
LT
P-e
xp
eri
me
nt
wi
th
int
rab
rai
n-e
lec
tro
de
s.
N
=
40
2′F
Le
nh
an
ce
dL
TP
.
(K
ru
ge
ta
l.,
19
94
)
2′F
,3
FL
60
mi
nb
ath
ap
pli
ca
tio
no
f0
.2
mM
2′F
L/
3F
L.
In
vit
ro:
Br
ain
sf
ro
m
8w
ee
ks
,w
ist
ar
rat
s,
ma
les
.
LT
P-e
xp
eri
me
nt
in
br
ain
s.
N
=
7–
10
/g
ro
up
.
2′F
Li
nc
rea
sed
po
pu
lat
ion
sp
ike
am
pli
tu
de
an
dfi
eld
ex
cit
ato
ry
po
sts
yn
ap
tic
po
ten
tia
l.3
FL
ha
dn
oe
ffe
ct
on
LT
P.
(M
att
hie
s
et
al.
,1
99
6)
3′S
L,
6′S
L
2/
4g
3′S
L/
6′S
L/
Le
qu
al
to
0.6
/1
.2
g/
kg
bo
dy
we
igh
to
rc
on
tro
lf
or
21
da
ys
(fe
ed
ing
3/
da
y)
.
In
viv
o:
Pig
s,
da
y-o
ld,
ful
l-t
erm
cro
ssb
red
.
Sia
an
aly
sis
in
br
ain
tis
su
ea
nd
gu
tm
icr
ob
iot
a
qu
an
tifi
ca
tio
n.
N
=
54
(4
+
5p
igs
pr
.
tre
atm
en
t).
3′S
La
nd
6′S
La
lte
red
th
eg
ut
mi
cro
bio
ta
an
di
nc
rea
sed
ga
nli
os
ide
-bo
un
dS
ia
in
th
ec
or
pu
sc
all
os
um
an
dc
ere
be
llu
m.
(Ja
co
bi
et
al.
,2
01
5)
3′S
L,
6′S
L
5%
of
die
tw
as
3′S
Lo
r6
′SL
for
2w
ee
ks
pr
ior
to
an
dd
ur
ing
str
ess
or
.
In
viv
o:
C5
7/
BL
6m
ice
,m
ale
s,
6–
8w
ee
ks
.
So
cia
ld
isr
up
tio
ns
tre
sso
r,
an
xie
ty
tes
ts
(o
pe
n
fie
ld
an
dl
igh
t/d
ark
pr
efe
ren
ce
tes
ts)
,
mi
cro
bio
ta
seq
ue
nc
ing
,b
rai
nc
ell
pr
oli
fer
ati
on
an
di
mm
atu
re
ne
ur
on
al
as
ses
sm
en
t.
N
=
9/
gr
ou
p.
3′S
Lo
r6
′SL
co
un
ter
ac
ted
th
es
tre
sso
r
ind
uc
ed
mi
cro
bia
l-c
ha
ng
ea
nd
he
lpe
d
ma
int
ain
no
rm
al
be
ha
vio
ro
n
tes
ts
of
an
xie
ty-
lik
eb
eh
av
ior
an
dn
or
ma
l
nu
mb
ers
of
im
ma
tu
re
ne
ur
on
s.
(T
arr
et
al.
,
20
15
)
2′F
L
Or
al
ad
mi
nis
tra
tio
n,
th
ro
ug
h
th
ed
iet
,
35
0m
g/
kg
,f
or
5w
ee
ks
(ra
ts)
or
12
we
ek
s(
mi
ce
).
In
on
es
tu
dy
,o
ral
ga
va
ge
,1
g/
kg
BW
in
rat
s.
In
viv
o:
Mi
ce
:M
ale
C5
7B
L/
6(
2–
3.5
mo
nt
hs
,
25
–3
0g
).
Ra
ts:
Ma
le
Sp
rag
ue
-D
aw
ley
(2
.5–
4m
on
th
s,
25
0–
30
0g
).
LT
P
ex
pe
rim
en
ts,
Int
ell
iC
ag
es
tu
dy
/S
kin
ne
r
bo
xt
est
s,
BD
NF
qu
ati
fic
ati
on
.
Mi
ce
:N
=
8–
28
/g
ro
up
Ra
ts:
N
=
7–
10
/g
ro
up
.
2′F
Lh
ad
po
ten
tia
tin
ge
ffe
ct
on
hip
po
ca
mp
al
LT
P
,i
mp
ro
ve
d
pe
rfo
rm
an
ce
in
va
rio
us
lea
rn
ing
tes
ts
an
di
nc
rea
sed
th
ee
xp
res
sio
n
of
ne
ur
oa
cti
ve
mo
lec
ule
s
(V
áz
qu
ez
et
al.
,2
01
5)
2′F
L
35
0m
g2
′FL
/k
go
fb
od
yw
eig
ht
pe
rd
ay
.
In
viv
o:
Ra
ts:
Ma
le
Sp
rag
ue
-D
aw
ley
(2
.5–
4m
on
th
s,
25
0–
30
0g
).
Ele
ctr
op
hy
sio
log
ica
ls
tu
die
s+
va
go
tom
ya
nd
Sk
inn
er
bo
xt
est
s.
N
=
10
/g
ro
up
.
2′F
Li
mp
ro
ve
dL
TP
an
do
pe
ran
t
co
nd
iti
on
ing
.V
ag
oto
my
inh
ibi
ted
th
e
eff
ec
to
f2
′FL
.
(V
az
qu
ez
et
al.
,2
01
6)
SL
Fr
om
2t
o3
2d
ay
so
fa
ge
rec
eiv
ing
on
eo
f
th
ef
oll
ow
ing
die
ts:
Co
nt
ro
l:
0m
gS
L/
L,
Lo
w:
13
0m
gS
L/
L,
Mo
de
rat
e:
38
0m
gS
L/
L,
Hi
gh
:7
60
mg
SL
/L
.
In
viv
o:
Int
ac
tm
ale
pig
s.
MR
Ia
sse
sse
me
nt
of
br
ain
de
ve
lop
me
nt
,S
ia
me
as
ur
em
en
ts
in
br
ain
an
dp
las
ma
.
N
=
38
.
In
pr
efr
on
tal
co
rte
xa
gr
ea
ter
pr
op
or
tio
n
of
bo
un
dS
ia
wa
sf
ou
nd
in
co
nt
ro
lp
igs
,
co
mp
are
dw
ith
low
an
dm
od
era
te
die
tar
yp
igs
,b
ut
we
re
no
td
iff
ere
nt
be
tw
ee
nc
on
tro
la
nd
hig
h
die
tar
yp
igs
.
Ra
tio
of
fre
e-t
o-b
ou
nd
Sia
wa
sd
ec
rea
sed
in
mo
de
rat
ed
iet
ary
pig
si
n
hip
po
ca
mp
us
.
(M
ud
d
et
al.
,2
01
7)
SL
Fr
om
2t
o3
2d
ay
so
fa
ge
rec
eiv
ing
co
nt
ro
ld
iet
or
SL
die
t(
SL
,1
90
mg
/1
00
g
mi
lk
rep
lac
er
po
wd
er
~
38
0m
gS
L/
L)
.
In
viv
o:
Int
ac
tm
ale
pig
s.
Be
ha
vio
ral
tes
tin
g(
no
ve
lo
bje
ct
rec
og
nit
ion
an
da
cti
vit
ya
na
lys
is)
.
N
=
36
.
Di
eta
ry
SL
did
no
ta
lte
rg
ro
wt
h
pe
rfo
rm
an
ce
,d
ev
elo
pm
en
to
f
rec
og
nit
ion
me
mo
ry
or
gr
os
ss
lee
p-r
ela
ted
be
ha
vio
rs.
(F
lem
ing
et
al.
,2
01
8)
Sia
,6
′SL
Va
ria
tin
gd
os
es
th
ro
ug
ho
ut
th
e
ex
pe
rim
en
ts:
A
do
se
as
low
as
~
20
0m
g/
kg
/d
ay
top
pin
ga
t2
50
0m
g/
kg
/d
ay
(se
eF
ig.
1d
for
th
ee
xa
ct
nu
mb
ers
).
In
viv
o:
Pr
eg
na
nt
Sp
rag
ue
-D
aw
ley
rat
s+
pu
ps
(co
mp
lex
set
up
,s
ee
sch
em
e1
in
th
ep
ap
er)
Sia
-an
aly
sis
in
br
ain
tis
su
e,
LT
P-m
ea
su
rem
en
ts
+
be
ha
vio
ral
an
d
int
ell
ige
nc
et
est
s(
No
ve
lO
bje
ct
Re
co
gn
iti
on
Te
st,
Y
Ma
ze
wi
th
Bl
oc
ke
dA
rm
Te
st
an
d
Int
ell
iC
ag
e®
)
N
=
47
Co
mp
lex
set
up
,s
ee
sch
em
e1
in
th
ep
ap
er)
.
Ra
ts
rec
eiv
ing
Sia
,e
sp
ec
ial
ly
as
6′S
L,
pe
rfo
rm
ed
be
tte
ri
nb
eh
av
ior
al
as
ses
sm
en
ta
nd
ha
di
mp
ro
ve
dL
TP
an
d
me
mo
ry
co
mp
are
dt
ot
he
co
nt
ro
lg
ro
up
.
(O
liv
ero
s
et
al.
,2
01
8)
2′F
L
Or
al
stu
dy
:1
g1
3 C
-2́′
FL
/k
gb
od
yw
eig
ht
or
sa
lin
ea
st
he
ve
hic
le
via
or
al
ga
va
ge
.
Sa
cri
fic
ed
aft
er
0.5
,1
,2
,3
,5
,9
,a
nd
15
h
(G
Fm
ice
aft
er
5+
12
h)
.
Int
rav
en
ou
sly
stu
dy
in
NM
RI
mi
ce
:
20
0m
g1
3 C
-2′
FL
/k
gb
od
yw
eig
ht
ev
ery
6h
,f
or
24
.
In
viv
o:
Ma
le
NM
RI
mi
ce
,8
we
ek
so
fa
ge
,
36
–4
7g
or
Ma
le
C3
H/
He
N
ax
en
ic
(G
F)
mi
ce
,6
we
ek
so
fa
ge
,2
9–
35
g.
De
ter
mi
na
tio
no
f1
3 C
-2′
FL
by
Ele
me
nt
al
An
aly
sis
—
Iso
top
eR
ati
oM
as
sS
pe
ctr
om
etr
y
(E
A-
IR
MS
)
Or
al
stu
dy
:
N_
GF
=
12
N_
NM
RI
=
40
.
Int
rav
en
ou
sly
_st
ud
y:
N_
NM
RI
=
8.
2′F
Ld
id
no
tr
ea
ch
th
eb
rai
ni
n
int
ac
t
for
m.
(K
un
tz
et
al.
,2
01
9)
SL
,3
′SL
,6
′SL
43
3
±
5m
g/
L.
3′S
L:6
′SL
rat
io
5:1
.
In
viv
o:
Pr
ete
rm
pig
s,
La
nd
rac
e×
Yo
rk
sh
ire
×
Du
ro
c,
bo
rn
on
da
y1
06
.
Be
ha
vio
ral
tes
ts,
MR
Ia
nd
tis
su
ea
na
lys
is.
N
=
46
.
SL
ad
mi
nis
tra
tio
ni
nc
rea
sed
co
gn
iti
ve
lev
el
of
pr
ete
rm
pig
st
ot
he
sa
me
as
th
e
ter
m
pig
sa
nd
up
reg
ula
ted
ge
ne
sr
ela
ted
to
sia
lic
ac
id
me
tab
oli
sm
(O
be
lit
z-
Ry
om
et
al.
,
20
19
)
SL
,3
′SL
,6
′SL
So
w
mi
lk
rep
lac
er
alo
ne
or
su
pp
lem
en
ted
wi
th
SL
s9
.5
g/
kg
(3
′SL
(7
.6
g/
kg
)a
nd
In
viv
o:
Th
ree
-da
y-o
ld
ma
le
do
me
sti
cp
igl
ets
(Su
s
N
=
15
–1
6/
gr
ou
p.
Sia
lyl
ate
dm
ilk
oli
go
sa
cc
ha
rid
es
alt
ere
d
im
po
rta
nt
br
ain
me
tab
oli
tes
an
d
(W
an
ge
ta
l.,
20
19
)
(co
nti
nu
ed
on
ne
xt
pa
ge)
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
9
Declaration of Competing Interest
Stine Dam Jepsen, Kristine Rothaus Christensen and Louise Kristine
Vigsnæs are currently employed at Glycom A/S, a company that pro-
duces human milk oligosaccharides. Other than that, there are no
known conflicts of interest associated with this publication.
Acknowledgement
The authors acknowledge Claus Heiner Bang-Berthelsen, senior
scientist at the National Food Institute, Technical University of
Denmark for excellent scientific advice, and Galina Skladtchikova,
Arpad Kovacs and Bruce McConnell for their support and the critical
review of the manuscript.
References
Allen, A. P., Hutch, W., Borre, Y. E., Kennedy, P. J., Temko, A., Boylan, G., ... Clarke, G.
(2016). Bifidobacterium longum 1714 as a translational psychobiotic: Modulation of
stress, electrophysiology and neurocognition in healthy volunteers. Translational
Psychiatry, 6(11), e939.
Arboleya, S., Watkins, C., Stanton, C., & Ross, R. P. (2016). Gut bifidobacteria populations
in human health and aging. Frontiers in Microbiology, 7(1204).
Arentsen, T., Raith, H., Qian, Y., Forssberg, H., & Diaz Heijtz, R. (2015). Host microbiota
modulates development of social preference in mice. Microbial Ecology in Health and
Disease, 26, 29719.
Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., ... Meta, H.
I. T. C. (2011). Enterotypes of the human gut microbiome. Nature, 473(7346),
174–180.
Asakuma, S., Hatakeyama, E., Urashima, T., Yoshida, E., Katayama, T., Yamamoto, K., ...
Kitaoka, M. (2011). Physiology of consumption of human milk oligosaccharides by
infant gut-associated bifidobacteria. The Journal of biological chemistry, 286(40),
34583–34592.
Avershina, E., Lundgård, K., Sekelja, M., Dotterud, C., Storrø, O., Øien, T., ... Rudi, K.
(2016). Transition from infant- to adult-like gut microbiota. Environmental
Microbiology, 18(7), 2226–2236.
Azad, M. B., Konya, T., Maughan, H., Guttman, D. S., Field, C. J., Chari, R. S., ...
Kozyrskyj, A. L. (2013). Gut microbiota of healthy Canadian infants: Profiles by mode
of delivery and infant diet at 4 months. Canadian Medical Association Journal, 185(5),
385.
Barile, D., Tao, N., Lebrilla, C., Coisson, J.-D., Arlorio, M., & German, B. (2009). Permeate
from cheese whey ultrafiltration is a source of milk oligosaccharides.
Barrett, E., Ross, R. P., O'Toole, P. W., Fitzgerald, G. F., & Stanton, C. (2012). γ-
Aminobutyric acid production by culturable bacteria from the human intestine.
Journal of Applied Microbiology, 113(2), 411–417.
Baxter, N. T., Schmidt, A. W., Venkataraman, A., Kim, K. S., Waldron, C., & Schmidt, T. M.
(2019). Dynamics of human gut microbiota and short-chain fatty acids in response to
dietary interventions with three fermentable fibers. mBio, 10(1), e02566–02518.
Bennet, R., Eriksson, M., & Nord, C. E. (2002). The fecal microflora of 1–3-month-old
infants during treatment with eight oral antibiotics. Infection, 30(3), 158–160.
Bercik, P., Denou, E., Collins, J., Jackson, W., Lu, J., Jury, J., ... Collins, S. M. (2011). The
intestinal microbiota affect central levels of brain-derived neurotropic factor and
behavior in mice. Gastroenterology, 141(2), 599–609.e593.
Berger, P. K., Plows, J. F., Jones, R. B., Alderete, T. L., Yonemitsu, C., Poulsen, M., ...
Goran, M. I. (2020). Human milk oligosaccharide 2’-fucosyllactose links feedings at 1
month to cognitive development at 24 months in infants of normal and overweight
mothers. PLoS ONE, 15(2), Article e0228323.
Berger, B., Porta, N., Foata, F., Grathwohl, D., Delley, M., Moine, D., ... Sprenger, N.
(2020). Linking human milk oligosaccharides, infant fecal community types, and
later risk to require antibiotics. mBio, 11(2), e03196–03119.
Bezirtzoglou, E., Tsiotsias, A., & Welling, G. W. (2011). Microbiota profile in feces of
breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH).
Anaerobe, 17(6), 478–482.
Bienenstock, J., Buck, R. H., Linke, H., Forsythe, P., Stanisz, A. M., & Kunze, W. A. (2013).
Fucosylated but not sialylated milk oligosaccharides diminish colon motor contrac-
tions. PLoS ONE, 8(10), Article e76236.
Boccuto, L., Chen, C.-F., Pittman, A. R., Skinner, C. D., McCartney, H. J., Jones, K., ...
Schwartz, C. E. (2013). Decreased tryptophan metabolism in patients with autism
spectrum disorders. Molecular Autism, 4(1), 16.
Bode, L. (2012). Human milk oligosaccharides: Every baby needs a sugar mama.
Glycobiology, 22(9), 1147–1162.
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., … Pettersson,
S. (2014). The gut microbiota influences blood-brain barrier permeability in mice.
Science Translational Medicine 6(263), 263ra158–263ra158.
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., ...
Cryan, J. F. (2011). Ingestion of Lactobacillus strain regulates emotional behavior
and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of
the National Academy of Sciences of the United States of America, 108(38),
16050–16055.
Burokas, A., Arboleya, S., Moloney, R. D., Peterson, V. L., Murphy, K., Clarke, G., ...Ta
bl
e2
(co
nti
nu
ed
)
Str
uc
tu
re(
s)
Co
nc
en
tra
tio
n+
du
rat
ion
Ty
pe
of
stu
dy
Inv
est
iga
tio
n
N
Ou
tco
me
Re
fer
en
ce
6′S
L(
1.9
g/
kg
))
or
ac
om
bin
ati
on
of
SL
s
an
d6
′si
aly
lla
cto
sa
mi
ne
9.5
g/
kg
(3
′SL
(7
.04
g/
kg
),
6′S
L(
1.7
4g
/k
g),
6′s
ial
yll
ac
tos
am
ine
(0
.72
g/
kg
))
for
35
da
ys
.
scr
ofa
–B
elg
ian
La
nd
rac
e,
La
rg
eW
hit
e,
La
nd
rac
ea
nd
Du
ro
c
br
ee
d)
we
igh
ing
1.8
–2
.2
kg
.
Br
ain
sp
ec
tra
we
re
ac
qu
ire
du
sin
ga
3T
Ma
gn
eti
cR
eso
na
nc
eS
pe
ctr
os
co
pic
(M
RS
)
sy
ste
m.
ne
ur
otr
an
sm
itt
ers
in
pig
let
s,
inc
lud
ing
my
oin
os
ito
l,
glu
tam
ate
an
dg
lut
am
ine
.
2′F
L
1,
2,
5a
nd
10
%
(w
/v
)i
nd
rin
kin
gw
ate
r
for
six
we
ek
s.
In
viv
o:
Ma
le
C5
7/
BL
6m
ice
,s
ix
we
ek
so
ld.
Di
et
stu
dy
:l
ow
fat
die
tv
s.
hig
hf
at
die
t+
/-
2′F
L.
N
=
6/
gr
ou
p.
2′F
Lm
od
ula
ted
th
eh
yp
erp
ha
gic
res
po
ns
et
oh
igh
-fa
td
iet
s,
alt
ere
dt
he
gu
t
mi
cro
bio
ta
an
dd
ec
rea
sed
infl
am
ma
tor
y
ma
rk
ers
infl
(L
ee
et
al.
,
20
20
)
2′F
L
Pr
etr
ea
tm
en
t:
2′F
L(
30
nm
ole
/1
5μ
g/
an
im
al
in
20
μl)
int
rac
ere
br
ov
en
tri
cu
lar
ly.
Po
st-
tre
atm
en
t:
2′F
L(
40
0m
g/
kg
/d
ay
)o
rv
eh
icl
e,
or
all
y
fed
to
th
ea
nim
als
on
ce
/d
ay
fro
m
da
ys
2–
7(
im
mu
no
his
toc
he
mi
str
y)
or
fro
m
da
ys
2t
o1
4(
br
om
od
eo
xy
ur
idi
ne
)a
fte
r
mi
dd
le
ce
reb
ral
art
ery
oc
clu
sio
n
In
viv
o:
Ad
ult
ma
le
Sp
rag
ue
-D
aw
ley
rat
s.
In
vit
ro:
Pr
im
ary
co
rti
ca
ln
eu
ro
na
lc
ell
sf
ro
m
tim
ep
reg
na
nt
Sp
rag
ue
-D
aw
ley
rat
s
(em
br
yo
s).
Str
ok
em
od
el
in
vit
ro
an
di
nv
ivo
.E
va
lua
tio
no
f
be
ha
vio
ral
me
as
ur
em
en
ts,
inf
arc
tio
n,
ne
ur
oa
cti
ve
bio
mo
lec
ule
s,
ne
ur
od
eg
en
era
tio
n
an
di
nfl
am
ma
tio
n
Se
ve
ral
diff
ere
nt
ex
pe
rim
en
ts:
Gr
ou
ps
ize
s
be
tw
ee
n6
an
d1
0.
2′F
Lr
ed
uc
ed
glu
tam
ate
-in
du
ce
dn
eu
ro
tox
ici
ty,
ap
op
tos
is,
an
dC
a+
+
infl
ux
in
pr
im
ary
ne
ur
on
al
cu
ltu
re.
Pr
e-
or
po
st-
tre
atm
en
t
wi
th
2′F
Lr
ed
uc
ed
br
ain
inf
arc
tio
n,
ne
ur
olo
gic
al
an
dm
oto
rd
efi
cit
sa
nd
infl
am
ma
tio
na
nd
inc
rea
sed
th
e
ex
pr
ess
ion
of
BD
NF
in
viv
o.
(W
ue
ta
l.,
20
20
)
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
10
Cryan, J. F. (2017). Targeting the microbiota-gut-brain axis: Prebiotics have anxio-
lytic and antidepressant-like effects and reverse the impact of chronic stress in mice.
Biological Psychiatry, 82(7), 472–487.
Cani, P. D., Lecourt, E., Dewulf, E. M., Sohet, F. M., Pachikian, B. D., Naslain, D., ...
Delzenne, N. M. (2009). Gut microbiota fermentation of prebiotics increases satie-
togenic and incretin gut peptide production with consequences for appetite sensation
and glucose response after a meal. The American Journal of Clinical Nutrition, 90(5),
1236–1243.
Cani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., ...
Delzenne, N. M. (2009). Changes in gut microbiota control inflammation in obese
mice through a mechanism involving GLP-2-driven improvement of gut permeability.
Gut, 58(8), 1091.
Chen, J.-L., Duan, W.-J., Luo, S., Li, S., Ma, X.-H., Hou, B.-N., ... Chen, Y.-B. (2017).
Ferulic acid attenuates brain microvascular endothelial cells damage caused by
oxygen-glucose deprivation via punctate-mitochondria-dependent mitophagy. Brain
Research, 1666, 17–26.
Clarke, T. B., Davis, K. M., Lysenko, E. S., Zhou, A. Y., Yu, Y., & Weiser, J. N. (2010).
Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate
immunity. Nature Medicine, 16(2), 228–231.
Clarke, G., Grenham, S., Scully, P., Fitzgerald, P., Moloney, R. D., Shanahan, F., ... Cryan,
J. F. (2013). The microbiome-gut-brain axis during early life regulates the hippo-
campal serotonergic system in a sex-dependent manner. Molecular Psychiatry, 18(6),
666–673.
Coppa, G. V., Pierani, P., Zampini, L., Carloni, I., Carlucci, A., & Gabrielli, O. (1999).
Oligosaccharides in human milk during different phases of lactation. Acta Paediatrica
Supplement, 88(430), 89–94.
Coulet, M., Phothirath, P., Allais, L., & Schilter, B. (2014). Pre-clinical safety evaluation of
the synthetic human milk, nature-identical, oligosaccharide 2′-O-Fucosyllactose
(2′FL). Regulatory Toxicology and Pharmacology, 68(1), 59–69.
Coulet, M., Phothirath, P., Constable, A., Marsden, E., & Schilter, B. (2013). Pre-clinical
safety assessment of the synthetic human milk, nature-identical, oligosaccharide
Lacto-N-neotetraose (LNnT). Food and Chemical Toxicology, 62, 528–537.
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S.,
Boehme, M., ... Dinan, T. G. (2019). The microbiota-gut-brain axis. Physiological
Reviews, 99(4), 1877–2013.
Dae Hee Kim, R.B.G., Woo, J., Cho, S. S., & Hong, J. H. (2018). Gastrointestinal tolerance
and safety of 3’-sialyllactose in subjects positive with helicobacter pylori: A pilot
study. EC Nutrition.
De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., …,
Lionetti, P. (2010). “Impact of diet in shaping gut microbiota revealed by a com-
parative study in children from Europe and rural Africa. Proceedings of the National
Academy of Sciences 107(33), 14691–14696.
DeCastro, M., Nankova, B. B., Shah, P., Patel, P., Mally, P. V., Mishra, R., & La Gamma, E.
F. (2005). Short chain fatty acids regulate tyrosine hydroxylase gene expression
through a cAMP-dependent signaling pathway. Molecular Brain Research, 142(1),
28–38.
Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J., & Dinan, T. G. (2008). The probiotic
Bifidobacteria infantis: An assessment of potential antidepressant properties in the
rat. Journal of Psychiatric Research, 43(2), 164–174.
Difilippo, E., Pan, F., Logtenberg, M., Willems, R., Braber, S., Fink-Gremmels, J., ...
Gruppen, H. (2016). Milk oligosaccharide variation in sow milk and milk oligo-
saccharide fermentation in piglet intestine. Journal of Agricultural and Food Chemistry,
64(10), 2087–2093.
Dogra, S., Sakwinska, O., Soh, S.-E., Ngom-Bru, C., Brück, W. M., Berger, B., …, Holbrook,
J. D. (2015). Dynamics of infant gut microbiota are influenced by delivery mode and
gestational duration and are associated with subsequent adiposity. mBio 6(1),
e02419–02414.
Donohoe, D. R., Garge, N., Zhang, X., Sun, W., O'Connell, T. M., Bunger, M. K., & Bultman,
S. J. (2011). The microbiome and butyrate regulate energy metabolism and autop-
hagy in the mammalian colon. Cell Metabolism, 13(5), 517–526.
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., ...
Weinberger, D. R. (2003). The BDNF val66met polymorphism affects activity-de-
pendent secretion of BDNF and human memory and hippocampal function. Cell,
112(2), 257–269.
Elison, E., Vigsnaes, L. K., Rindom Krogsgaard, L., Rasmussen, J., Sørensen, N.,
McConnell, B., ... Bytzer, P. (2016). Oral supplementation of healthy adults with 2′-O-
fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal mi-
crobiota. British Journal of Nutrition, 116(8), 1356–1368.
Farhin, S., Wong, A., Delungahawatta, T., Amin, J. Y., Bienenstock, J., Buck, R., & Kunze,
W. A. (2019). Restraint stress induced gut dysmotility is diminished by a milk oli-
gosaccharide (2'-fucosyllactose) in vitro. PLoS ONE, 14(4), e0215151.
Fleming, S. A., Chichlowski, M., Berg, B. M., Donovan, S. M., & Dilger, R. N. (2018).
Dietary sialyllactose does not influence measures of recognition memory or diurnal
activity in the young pig. Nutrients, 10(4), 395.
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., ...
Keshavarzian, A. (2011). Increased intestinal permeability correlates with sigmoid
mucosa alpha-synuclein staining and endotoxin exposure markers in early
Parkinson's disease. PLoS ONE, 6(12), e28032.
Gagliardi, A., Totino, V., Cacciotti, F., Iebba, V., Neroni, B., Bonfiglio, G., ... Schippa, S.
(2018). Rebuilding the gut microbiota ecosystem. International Journal of
Environmental Research and Public Health, 15(8).
Gao, K., Pi, Y., Mu, C.-L., Farzi, A., Liu, Z., & Zhu, W.-Y. (2019). Increasing carbohydrate
availability in the hindgut promotes hypothalamic neurotransmitter synthesis:
Aromatic amino acids linking the microbiota–brain axis. Journal of Neurochemistry,
149(5), 641–659.
Gareau, M. G., Wine, E., Rodrigues, D. M., Cho, J. H., Whary, M. T., Philpott, D. J., ...
Sherman, P. M. (2011). Bacterial infection causes stress-induced memory dysfunction
in mice. Gut, 60(3), 307.
Ge, X., Ding, C., Zhao, W., Xu, L., Tian, H., Gong, J., ... Li, N. (2017). Antibiotics-induced
depletion of mice microbiota induces changes in host serotonin biosynthesis and
intestinal motility. Journal of Translational Medicine, 15(1), 13.
Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., …,
Reid, G. (2017). Expert consensus document: The International Scientific Association
for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope
of prebiotics. Nature Reviews Gastroenterology & Hepatology 14, 491.
Goehring, K. C., Marriage, B. J., Oliver, J. S., Wilder, J. A., Barrett, E. G., & Buck, R. H.
(2016). Similar to those who are breastfed, infants fed a formula containing 2′-fu-
cosyllactose have lower inflammatory cytokines in a randomized controlled trial. The
Journal of Nutrition, 146(12), 2559–2566.
Grimaldi, R., Gibson, G. R., Vulevic, J., Giallourou, N., Castro-Mejía, J. L., Hansen, L. H.,
... Costabile, A. (2018). A prebiotic intervention study in children with autism
spectrum disorders (ASDs). Microbiome, 6(1), 133.
Gustafsson, B. E. (1959). Vitamin K deficiency in germfree rats*. Annals of the New York
Academy of Sciences, 78(1), 166–174.
Hadizadeh, M., Hamidi, G. A., & Salami, M. (2019). Probiotic supplementation improves
the cognitive function and the anxiety-like behaviors in the stressed rats. Iranian
Journal of Basic Medical Sciences, 22(5), 506–514.
Haghikia, A., Jörg, S., Duscha, A., Berg, J., Manzel, A., Waschbisch, A., ... Linker, R. A.
(2015). Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity
via the Small Intestine. Immunity, 43(4), 817–829.
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F.,
& Weinberger, D. R. (2003). Brain-derived neurotrophic factor val66met poly-
morphism affects human memory-related hippocampal activity and predicts memory
performance. The Journal of Neuroscience: The Official Journal of The Society for
Neuroscience, 23(17), 6690–6694.
Hata, T., Asano, Y., Yoshihara, K., Kimura-Todani, T., Miyata, N., Zhang, X.-T., ... Sudo, N.
(2017). Regulation of gut luminal serotonin by commensal microbiota in mice. PLoS
ONE, 12(7), Article e0180745.
Heijtz, R. D., Wang, S., Anuar, F., Qian, Y., Björkholm, B., Samuelsson, A., ... Pettersson, S.
(2011). Normal gut microbiota modulates brain development and behavior.
Proceedings of the National Academy of Sciences, 108(7), 3047.
Hennet, T., & Borsig, L. (2016). Breastfed at Tiffany's. Trends in Biochemical Sciences,
41(6), 508–518.
Hu, J., Nomura, Y., Bashir, A., Fernandez-Hernandez, H., Itzkowitz, S., Pei, Z., ... Peter, I.
(2013). Diversified microbiota of meconium is affected by maternal diabetes status.
PLoS ONE, 8(11), e78257.
Husebye, E., Hellström, P. M., Sundler, F., Chen, J., & Midtvedt, T. (2001). Influence of
microbial species on small intestinal myoelectric activity and transit in germ-free rats.
American Journal of Physiology-Gastrointestinal and Liver Physiology, 280(3),
G368–G380.
Iribarren, C., Törnblom, H., Aziz, I., Magnusson, M. K., Sundin, J., Vigsnæs, L. K., ...
Simrén, M. (2020). Human milk oligosaccharide supplementation in irritable bowel
syndrome patients: A parallel, randomized, double-blind, placebo-controlled study.
Neurogastroenterology & Motility, e13920 n/a(n/a).
Jacobi, S. K., Yatsunenko, T., Li, D., Dasgupta, S., Yu, R. K., Berg, B. M., ... Odle, J. (2015).
Dietary isomers of sialyllactose increase ganglioside sialic acid concentrations in the
corpus callosum and cerebellum and modulate the colonic microbiota of formula-fed
piglets. The Journal of Nutrition, 146(2), 200–208.
Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., ... Ruan, B. (2015). Altered fecal
microbiota composition in patients with major depressive disorder. Brain, Behavior,
and Immunity, 48, 186–194.
Jürgens, B., Hainz, U., Fuchs, D., Felzmann, T., & Heitger, A. (2009). Interferon-γ-trig-
gered indoleamine 2,3-dioxygenase competence in human monocyte-derived den-
dritic cells induces regulatory activity in allogeneic T cells. Blood, 114, 3235–3243.
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., ...
Palva, A. (2007). The fecal microbiota of irritable bowel syndrome patients differs
significantly from that of healthy subjects. Gastroenterology, 133(1), 24–33.
Kato, K., Odamaki, T., Mitsuyama, E., Sugahara, H., Xiao, J.-Z., & Osawa, R. (2017). Age-
related changes in the composition of gut bifidobacterium species. Current
Microbiology, 74(8), 987–995.
Kazemi, A., Noorbala, A. A., Azam, K., Eskandari, M. H., & Djafarian, K. (2019). Effect of
probiotic and prebiotic vs placebo on psychological outcomes in patients with major
depressive disorder: A randomized clinical trial. Clinical Nutrition, 38(2), 522–528.
Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., …, Dinan, T. G.
(2016). Transferring the blues: Depression-associated gut microbiota induces neu-
robehavioural changes in the rat. Journal of Psychiatric Research 82, 109–118.
Kelly, S. M., O’Callaghan, J., Kinsella, M., & van Sinderen, D. (2018). Characterisation of a
hydroxycinnamic acid esterase from the bifidobacterium longum subsp. Longum
Taxon. Frontiers in Microbiology, 9, 2690.
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., ...
Shannon, K. M. (2015). Colonic bacterial composition in Parkinson's disease.
Movement Disorders, 30(10), 1351–1360.
Khan, N. A., Raine, L. B., Drollette, E. S., Scudder, M. R., Kramer, A. F., & Hillman, C. H.
(2015). Dietary fiber is positively associated with cognitive control among pre-
pubertal children. The Journal of Nutrition, 145(1), 143–149.
Komatsuzaki, N., Nakamura, T., Kimura, T., & Shima, J. (2008). Characterization of
glutamate decarboxylase from a high γ-aminobutyric acid (GABA)-producer, lacto-
bacillus paracasei. Bioscience, Biotechnology, and Biochemistry, 72(2), 278–285.
Krug, M., Wagner, M., Staak, S., & Smalla, K.-H. (1994). Fucose and fucose-containing
sugar epitopes enhance hippocampal long-term potentiation in the freely moving rat.
Brain Research, 643(1), 130–135.
Kuntz, S., Kunz, C., Borsch, C., Vazquez, E., Buck, R., Reutzel, M., ... Rudloff, S. (2019).
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
11
Metabolic fate and distribution of 2́-fucosyllactose: Direct influence on gut microbial
activity but not on brain. Molecular Nutrition & Food Research, 63(13), e1900035.
Kunz, C., Meyer, C., Collado, M. C., Geiger, L., García-Mantrana, I., Bertua-Ríos, B., ...
Rudloff, S. (2017). Influence of gestational age, secretor, and lewis blood group status
on the oligosaccharide content of human milk. Journal of Pediatric Gastroenterology
and Nutrition, 64(5), 789–798.
Lane, J. A., O'Callaghan, J., Carrington, S. D., & Hickey, R. M. (2013). Transcriptional
response of HT-29 intestinal epithelial cells to human and bovine milk oligo-
saccharides. British Journal of Nutrition, 110(12), 2127–2137.
Lawson, M. A. E., O’Neill, I. J., Kujawska, M., Gowrinadh Javvadi, S., Wijeyesekera, A.,
Flegg, Z., ... Hall, L. J. (2019). Breast milk-derived human milk oligosaccharides
promote Bifidobacterium interactions within a single ecosystem. The ISME Journal.
Lee, S., Goodson, M., Vang, W., Kalanetra, K., Barile, D., & Raybould, H. (2020). 2'-fu-
cosyllactose supplementation improves gut-brain signaling and diet-induced obese
phenotype and changes the gut microbiota in high fat-fed mice. Nutrients, 12(4).
Liu, S., Li, E., Sun, Z., Fu, D., Duan, G., Jiang, M., ... Zheng, P. (2019). Altered gut mi-
crobiota and short chain fatty acids in Chinese children with autism spectrum dis-
order. Scientific Reports, 9(1), 287.
LoCascio, R. G., Ninonuevo, M. R., Freeman, S. L., Sela, D. A., Grimm, R., Lebrilla, C. B., ...
German, J. B. (2007). Glycoprofiling of bifidobacterial consumption of human milk
oligosaccharides demonstrates strain specific, preferential consumption of small
chain glycans secreted in early human lactation. Journal of Agricultural and Food
Chemistry, 55(22), 8914–8919.
Lowe, S. L., Francis, P. T., Procter, A. W., Palmer, A. M., Davison, A. N., & Bowen, D. M.
(1988). Gamma-aminobutyric acid concentration in brain tissue at two stages of
Alzheimer's disease. Brain, 111(4), 785–799.
Lucas, A., Morley, R., Cole, T. J., Lister, G., & Leeson-Payne, C. (1992). Breast milk and
subsequent intelligence quotient in children born preterm. The Lancet, 339(8788),
261–264.
Lucas, A., Morley, R., Cole, T. J., Lucas, P. J., Gore, S. M., Crowle, P., ... Powell, R. (1990).
Early diet in preterm babies and developmental status at 18 months. The Lancet,
335(8704), 1477–1481.
Lukić, I., Getselter, D., Koren, O., & Elliott, E. (2019). Role of tryptophan in microbiota-
induced depressive-like behavior: Evidence from tryptophan depletion study.
Frontiers in Behavioral Neuroscience, 13, 123.
Luo, J., Wang, T., Liang, S., Hu, X., Li, W., & Jin, F. (2014). Ingestion of Lactobacillus
strain reduces anxiety and improves cognitive function in the hyperammonemia rat.
Science China Life Sciences, 57(3), 327–335.
Madan, J. C., Hoen, A. G., Lundgren, S. N., Farzan, S. F., Cottingham, K. L., Morrison, H.
G., ... Karagas, M. R. (2016). Association of cesarean delivery and formula supple-
mentation with the intestinal microbiome of 6-week-old infants. JAMA Pediatrics,
170(3), 212–219.
Marcobal, A., Barboza, M., Froehlich, J. W., Block, D. E., German, J. B., Lebrilla, C. B., &
Mills, D. A. (2010). Consumption of human milk oligosaccharides by gut-related
microbes. Journal of Agricultural and Food Chemistry, 58(9), 5334–5340.
Martín, M. J., Martín-Sosa, S., García-Pardo, L. A., & Hueso, P. (2001). Distribution of
bovine milk sialoglycoconjugates during lactation. Journal of Dairy Science, 84(5),
995–1000.
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Di, Y., ... Mackay, C. R.
(2009). Regulation of inflammatory responses by gut microbiota and chemoattractant
receptor GPR43. Nature, 461(7268), 1282–1286.
Mastromarino, P., Capobianco, D., Campagna, G., Laforgia, N., Drimaco, P., Dileone, A., &
Baldassarre, M. E. (2014). Correlation between lactoferrin and beneficial microbiota
in breast milk and infant’s feces. BioMetals, 27(5), 1077–1086.
Matthies, H., Staak, S., & Krug, M. (1996). Fucose and fucosyllactose enhance in-vitro
hippocampal long-term potentiation. Brain Research, 725(2), 276–280.
Maurya, D. K., & Devasagayam, T. P. A. (2010). Antioxidant and prooxidant nature of
hydroxycinnamic acid derivatives ferulic and caffeic acids. Food and Chemical
Toxicology, 48(12), 3369–3373.
Messaoudi, M., Lalonde, R., Violle, N., Javelot, H., Desor, D., Nejdi, A., ... Cazaubiel, J.-M.
(2011). Assessment of psychotropic-like properties of a probiotic formulation
(Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and
human subjects. British Journal of Nutrition, 105(5), 755–764.
Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M.
(2017). Progression of Parkinson's disease is associated with gut dysbiosis: Two-year
follow-up study. PLoS ONE, 12(11), Article e0187307.
Monaco, M. H., Kim, D. H., Gurung, R. B., & Donovan, S. M. (2020). Evaluation of 6'-
sialyllactose sodium salt supplementation to formula on growth and clinical para-
meters in neonatal piglets. Nutrients, 12(4).
Mudd, A. T., Fleming, S. A., Labhart, B., Chichlowski, M., Berg, B. M., Donovan, S. M., &
Dilger, R. N. (2017). Dietary sialyllactose influences sialic acid concentrations in the
prefrontal cortex and magnetic resonance imaging measures in corpus callosum of
young pigs. Nutrients, 9(12), 1297.
Nankova, B. B., Agarwal, R., MacFabe, D. F., & La Gamma, E. F. (2014). Enteric bacterial
metabolites propionic and butyric acid modulate gene expression, including CREB-
dependent catecholaminergic neurotransmission, in PC12 cells–possible relevance to
autism spectrum disorders. PLoS ONE, 9(8), e103740.
Nissanka, N., & Moraes, C. T. (2018). Mitochondrial DNA damage and reactive oxygen
species in neurodegenerative disease. FEBS Letters, 592(5), 728–742.
Obelitz-Ryom, K., Bering, S. B., Overgaard, S. H., Eskildsen, S. F., Ringgaard, S., Olesen, J.
L., ... Thymann, T. (2019). Bovine milk oligosaccharides with sialyllactose improves
cognition in preterm pigs. Nutrients, 11(6).
Odamaki, T., Kato, K., Sugahara, H., Hashikura, N., Takahashi, S., Xiao, J.-Z., ... Osawa, R.
(2016). Age-related changes in gut microbiota composition from newborn to cen-
tenarian: A cross-sectional study. BMC Microbiology, 16(1), 90.
Ogiwara, T., Satoh, K., Kadoma, Y., Murakami, Y., Unten, S., Atsumi, T., ... Fujisawa, S.
(2002). Radical scavenging activity and cytotoxicity of ferulic acid. Anticancer
Research, 22, 2711–2717.
Oliveros, E., Vázquez, E., Barranco, A., Ramírez, M., Gruart, A., Delgado-García, J. M., ...
Martín, M. J. (2018). Sialic acid and sialylated oligosaccharide supplementation
during lactation improves learning and memory in rats. Nutrients, 10(10), 1519.
Owens, M. J., & Nemeroff, C. B. (1994). Role of serotonin in the pathophysiology of
depression: Focus on the serotonin transporter. Clinical Chemistry, 40(2), 288.
Özoǧul, F., Kuley, E., Özoǧul, Y., & Özoǧul, I. (2012). The function of lactic acid bacteria
on biogenic amines production by food-borne pathogens in arginine decarboxylase
broth. Food Science and Technology Research, 18(6), 795–804.
Parschat, K., Oehme, A., Leuschner, J., Jennewein, S., & Parkot, J. (2020). A safety
evaluation of mixed human milk oligosaccharides in rats. Food and Chemical
Toxicology, 136, Article 111118.
Phipps, K. R., Baldwin, N., Lynch, B., Flaxmer, J., Šoltésová, A., Gilby, B., ... Röhrig, C. H.
(2018). Safety evaluation of a mixture of the human-identical milk oligosaccharides
2′-fucosyllactose and difucosyllactose. Food and Chemical Toxicology, 120, 552–565.
Phipps, K. R., Baldwin, N., Lynch, B., Stannard, D. R., Šoltesová, A., Gilby, B., ... Röhrig, C.
H. (2018). Preclinical safety evaluation of the human-identical milk oligosaccharide
lacto-N-tetraose. Regulatory Toxicology and Pharmacology, 99, 260–273.
Phipps, K. R., Baldwin, N. J., Lynch, B., Stannard, D. R., Šoltésová, A., Gilby, B., ... Röhrig,
C. H. (2019a). Toxicological safety assessment of the human-identical milk oligo-
saccharide 3′-sialyllactose sodium salt. Journal of Applied Toxicology, 39(10),
1378–1393.
Phipps, K. R., Baldwin, N. J., Lynch, B., Stannard, D. R., Šoltésová, A., Gilby, B., ... Röhrig,
C. H. (2019b). Toxicological safety evaluation of the human-identical milk oligo-
saccharide 6′-sialyllactose sodium salt. Journal of Applied Toxicology, 39(10),
1444–1461.
Picone, P., Nuzzo, D., & Di Carlo, M. (2013). Ferulic acid: A natural antioxidant against
oxidative stress induced by oligomeric A-beta on sea urchin embryo. The Biological
Bulletin, 224(1), 18–28.
Pinto-Sanchez, M. I., Hall, G. B., Ghajar, K., Nardelli, A., Bolino, C., Lau, J. T., ... Bercik, P.
(2017). Probiotic bifidobacterium longum NCC3001 reduces depression scores and
alters brain activity: A pilot study in patients with irritable bowel syndrome.
Gastroenterology, 153(2), 448–459.e448.
Pitt, J., Chan, M., Gibson, C., Hasselwander, O., Lim, A., Mukerji, P., ... Roper, J. M.
(2019). Safety assessment of the biotechnologically produced human-identical milk
oligosaccharide 3-Fucosyllactose (3-FL). Food and Chemical Toxicology, 134, Article
110818.
Puccio, G., Alliet, P., Cajozzo, C., Janssens, E., Corsello, G., Sprenger, N., ... Steenhout, P.
(2017). Effects of infant formula with human milk oligosaccharides on growth and
morbidity: A randomized multicenter trial. Journal of Pediatric Gastroenterology and
Nutrition, 64(4), 624–631.
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., ... Meta, H. I. T. C.
(2010). A human gut microbial gene catalogue established by metagenomic se-
quencing. Nature, 464(7285), 59–65.
Rajilić-Stojanović, M., Heilig, H. G. H. J., Tims, S., Zoetendal, E. G., & de Vos, W. M.
(2013). Long-term monitoring of the human intestinal microbiota composition.
Environmental Microbiology, 15(4), 1146–1159.
Rauskolb, S., Zagrebelsky, M., Dreznjak, A., Deogracias, R., Matsumoto, T., Wiese, S., ...
Barde, Y.-A. (2010). Global deprivation of brain-derived neurotrophic factor in the
CNS reveals an area-specific requirement for dendritic growth. The Journal of
Neuroscience: The Official Journal of the Society for Neuroscience, 30(5), 1739–1749.
Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., &
Mele, M. C. (2019). What is the healthy gut microbiota composition? A changing
ecosystem across age, environment, diet, and diseases. Microorganisms, 7(1), 14.
Rivière, A., Gagnon, M., Weckx, S., Roy, D., & De Vuyst, L. (2015). Mutual cross-feeding
interactions between bifidobacterium longum subsp. longum NCC2705 and eu-
bacterium rectale ATCC 33656 explain the bifidogenic and butyrogenic effects of
arabinoxylan oligosaccharides. Applied and Environmental Microbiology, 81(22),
7767–7781.
Rudzki, L., Ostrowska, L., Pawlak, D., Małus, A., Pawlak, K., Waszkiewicz, N., & Szulc, A.
(2019). Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration
and improves cognitive functions in patients with major depression: A double-blind,
randomized, placebo controlled study. Psychoneuroendocrinology, 100, 213–222.
Ruiz-Palacios, G. M., Cervantes, L. E., Ramos, P., Chavez-Munguia, B., & Newburg, D. S.
(2003). Campylobacter jejuni Binds Intestinal H(O) Antigen (Fucα1, 2Galβ1,
4GlcNAc), and Fucosyloligosaccharides of Human Milk Inhibit Its Binding and
Infection. Journal of Biological Chemistry, 278(16), 14112–14120.
Şahin, T. D., Karson, A., Balcı, F., Yazır, Y., Bayramgürler, D., & Utkan, T. (2015). TNF-
alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels
in the unpredictable chronic mild stress rat model of depression. Behavioural Brain
Research, 292, 233–240.
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., ...
Mazmanian, S. K. (2016). Gut microbiota regulate motor deficits and neuroin-
flammation in a model of Parkinson’s Disease. Cell, 167(6), 1469–1480.e1412.
Samuel, B. S., Shaito, A., Motoike, T., Rey, F. E., Backhed, F., Manchester, J. K., ...
Gordon, J. I. (2008). Effects of the gut microbiota on host adiposity are modulated by
the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of
the National Academy of Sciences, 105(43), 16767–16772.
Savignac, H. M., Corona, G., Mills, H., Chen, L., Spencer, J. P. E., Tzortzis, G., & Burnet, P.
W. J. (2013). Prebiotic feeding elevates central brain derived neurotrophic factor, N-
methyl-d-aspartate receptor subunits and d-serine. Neurochemistry International,
63(8), 756–764.
Schengrund, C.-L. (2015). Gangliosides: Glycosphingolipids essential for normal neural
development and function. Trends in Biochemical Sciences, 40(7), 397–406.
Schmidt, K., Cowen, P. J., Harmer, C. J., Tzortzis, G., Errington, S., & Burnet, P. W. J.
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
12
(2015). Prebiotic intake reduces the waking cortisol response and alters emotional
bias in healthy volunteers. Psychopharmacology (Berl), 232(10), 1793–1801.
Schroeder, F. A., Lin, C. L., Crusio, W. E., & Akbarian, S. (2007). Antidepressant-like
effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biological
Psychiatry, 62(1), 55–64.
Schwab, C., Ruscheweyh, H.-J., Bunesova, V., Pham, V. T., Beerenwinkel, N., & Lacroix,
C. (2017). Trophic interactions of infant bifidobacteria and eubacterium hallii during
L-fucose and fucosyllactose degradation. Frontiers in Microbiology, 8, 95.
Siragusa, S., De Angelis, M., Di Cagno, R., Rizzello, C. G., Coda, R., & Gobbetti, M. (2007).
Synthesis of γ-aminobutyric acid by lactic acid bacteria isolated from a variety of
Italian Cheeses. Applied and Environmental Microbiology, 73(22), 7283–7290.
Stewart, C. J., Ajami, N. J., O’Brien, J. L., Hutchinson, D. S., Smith, D. P., Wong, M. C., ...
Petrosino, J. F. (2018). Temporal development of the gut microbiome in early
childhood from the TEDDY study. Nature, 562(7728), 583–588.
Strand, A. D., Baquet, Z. C., Aragaki, A. K., Holmans, P., Yang, L., Cleren, C., ... Jones, K.
R. (2007). Expression profiling of huntington's disease models suggests that brain-
derived neurotrophic factor depletion plays a major role in striatal degeneration. The
Journal of Neuroscience, 27(43), 11758–11768.
Strandwitz, P., Kim, K. H., Terekhova, D., Liu, J. K., Sharma, A., Levering, J., ... Lewis, K.
(2019). GABA-modulating bacteria of the human gut microbiota. Nature Microbiology,
4(3), 396–403.
Szwajgier, D., & Anna, D. (2010). “Novel ferulic acid esterases from Bifidobacterium sp.
produced on selected synthetic and natural carbon sources. Acta Scientiarum
Polonorum: Technologia Alimentaria, 9.
Tao, N., DePeters, E. J., Freeman, S., German, J. B., Grimm, R., & Lebrilla, C. B. (2008).
Bovine milk glycome. Journal of Dairy Science, 91(10), 3768–3778.
Tarr, A. J., Galley, J. D., Fisher, S. E., Chichlowski, M., Berg, B. M., & Bailey, M. T. (2015).
The prebiotics 3'Sialyllactose and 6'Sialyllactose diminish stressor-induced anxiety-
like behavior and colonic microbiota alterations: Evidence for effects on the gut-brain
axis. Brain, Behavior, and Immunity, 50, 166–177.
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., ...
Gribble, F. M. (2012). Short-chain fatty acids stimulate glucagon-like peptide-1 se-
cretion via the G-protein-coupled receptor FFAR2. Diabetes, 61(2), 364–371.
Tomaro-Duchesneau, C., Saha, S., Malhotra, M., Coussa-Charley, M., Kahouli, I., Jones, M.
L., ... Prakash, S. (2012). Probiotic ferulic acid esterase active lactobacillus fer-
mentum NCIMB 5221 APA microcapsules for oral delivery: Preparation and in vitro
characterization. Pharmaceuticals (Basel, Switzerland), 5(2), 236–248.
Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., &
Ostatnikova, D. (2015). Gastrointestinal microbiota in children with autism in
Slovakia. Physiology & Behavior, 138, 179–187.
Tonon, K. M., Miranda, A., Abrão, A. C. F. V., de Morais, M. B., & Morais, T. B. (2019).
Validation and application of a method for the simultaneous absolute quantification
of 16 neutral and acidic human milk oligosaccharides by graphitized carbon liquid
chromatography – electrospray ionization – mass spectrometry. Food Chemistry, 274,
691–697.
Turner, P. V. (2018). The role of the gut microbiota on animal model reproducibility.
Animal Models and Experimental Medicine, 1(2), 109–115.
Val-Laillet, D., Guérin, S., Coquery, N., Nogret, I., Formal, M., Romé, V., ... Segain, J.-P.
(2018). Oral sodium butyrate impacts brain metabolism and hippocampal neuro-
genesis, with limited effects on gut anatomy and function in pigs. The FASEB Journal,
32(4), 2160–2171.
Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., ... Raes,
J. (2019). The neuroactive potential of the human gut microbiota in quality of life
and depression. Nature Microbiology, 4(4), 623–632.
Vazquez, E., Barranco, A., Ramirez, M., Gruart, A., Delgado-Garcia, J. M., Jimenez, M. L.,
... Rueda, R. (2016). Dietary 2'-fucosyllactose enhances operant conditioning and
long-term potentiation via gut-brain communication through the vagus nerve in ro-
dents. PLoS ONE, 11(11), e0166070.
Vázquez, E., Barranco, A., Ramírez, M., Gruart, A., Delgado-García, J. M., Martínez-Lara,
E., ... Rueda, R. (2015). Effects of a human milk oligosaccharide, 2′-fucosyllactose, on
hippocampal long-term potentiation and learning capabilities in rodents. The Journal
of Nutritional Biochemistry, 26(5), 455–465.
Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S.
C., ... Rey, F. E. (2017). Gut microbiome alterations in Alzheimer’s disease. Scientific
Reports, 7(1), 13537.
Wang, B. (2009). Sialic acid is an essential nutrient for brain development and cognition.
Annual Review of Nutrition, 29(1), 177–222.
Wang, H. X., Chen, Y., Haque, Z., de Veer, M., Egan, G., & Wang, B. (2019). Sialylated
milk oligosaccharides alter neurotransmitters and brain metabolites in piglets: An In
vivo magnetic resonance spectroscopic (MRS) study. Nutritional Neuroscience, 1–11.
Wang, B., McVeagh, P., Petocz, P., & Brand-Miller, J. (2003). Brain ganglioside and
glycoprotein sialic acid in breastfed compared with formula-fed infants. The American
Journal of Clinical Nutrition, 78(5), 1024–1029.
Wang, B., Yu, B., Karim, M., Hu, H., Sun, Y., McGreevy, P., ... Brand-Miller, J. (2007).
Dietary sialic acid supplementation improves learning and memory in piglets. The
American Journal of Clinical Nutrition, 85(2), 561–569.
Ward, N. L., & Hagg, T. (2000). BDNF is needed for postnatal maturation of basal fore-
brain and neostriatum cholinergic neurons in vivo. Experimental Neurology, 162(2),
297–310.
Weichert, S., Jennewein, S., Hüfner, E., Weiss, C., Borkowski, J., Putze, J., & Schroten, H.
(2013). Bioengineered 2'-fucosyllactose and 3-fucosyllactose inhibit the adhesion of
Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory
cell lines. Nutrition Research, 33(10), 831–838.
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., ...
Chervonsky, A. V. (2008). Innate immunity and intestinal microbiota in the devel-
opment of Type 1 diabetes. Nature, 455(7216), 1109–1113.
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G.
(2009). Metabolomics analysis reveals large effects of gut microflora on mammalian
blood metabolites. Proceedings of the National Academy of Sciences, 106(10),
3698–3703.
Wilkins, L. J., Monga, M., & Miller, A. W. (2019). Defining dysbiosis for a cluster of
chronic diseases. Scientific Reports, 9(1), 12918.
Wolever, T. M. S., & Chiasson, J.-L. (2000). Acarbose raises serum butyrate in human
subjects withimpaired glucose tolerance. British Journal of Nutrition, 84(1), 57–61.
Wu, K.-J., Chen, Y.-H., Bae, E.-K., Song, Y., Min, W., & Yu, S.-J. (2020). Human milk
oligosaccharide 2′-fucosyllactose reduces neurodegeneration in stroke brain.
Translational Stroke Research.
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., ... Lewis, J.
D. (2011). Linking long-term dietary patterns with gut microbial enterotypes. Science
(New York, N.Y.), 334(6052), 105–108.
Xu, M., Xu, X., Li, J., & Li, F. (2019). Association between gut microbiota and autism
spectrum disorder: A systematic review and meta-analysis. Frontiers in Psychiatry, 10,
473.
Yabe, T., Hirahara, H., Harada, N., Ito, N., Nagai, T., Sanagi, T., & Yamada, H. (2010).
Ferulic acid induces neural progenitor cell proliferation in vitro and in vivo.
Neuroscience, 165(2), 515–524.
Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., ... Hsiao, E. Y. (2015).
Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis.
Cell, 161(2), 264–276.
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras,
M., ... Gordon, J. I. (2012). Human gut microbiome viewed across age and geography.
Nature, 486(7402), 222–227.
Yu, Z.-T., Chen, C., Kling, D. E., Liu, B., McCoy, J. M., Merighi, M., ... Newburg, D. S.
(2013). The principal fucosylated oligosaccharides of human milk exhibit prebiotic
properties on cultured infant microbiota. Glycobiology, 23(2), 169–177.
Yu, Z.-T., Chen, C., & Newburg, D. S. (2013). Utilization of major fucosylated and sia-
lylated human milk oligosaccharides by isolated human gut microbes. Glycobiology,
23(11), 1281–1292.
Zhang, W., Yan, J., Wu, L., Yu, Y., Ye, R. D., Zhang, Y., & Liang, X. (2019). In vitro
immunomodulatory effects of human milk oligosaccharides on murine macrophage
RAW264.7 cells. Carbohydrate Polymers, 207, 230–238.
Zhuang, X., Li, T., Li, M., Huang, S., Qiu, Y., Feng, R., ... Zeng, Z. (2019). Systematic
review and meta-analysis: short-chain fatty acid characterization in patients with
inflammatory bowel disease. Inflammatory Bowel Diseases.
Further reading
Neufeld, K. M., Kang, N., Bienenstock, J., & Foster, J. A. (2011). Reduced anxiety-like
behavior and central neurochemical change in germ-free mice. Neurogastroenterology
& Motility, 23(3), 255–e119.
A.H. Al-Khafaji, et al. Journal of Functional Foods 74 (2020) 104176
13
